No retraction, correction or concern found when last checked on Oct 17, 2026.

From in vitro to in vivo Models of Bacterial Biofilm-Related Infections

David Lebeaux, Ashwini Chauhan, Olaya Rendueles and 1 more

Pathogens · 2013 · Review · CC BY

doi:10.3390/pathogens2020288

Abstract

The influence of microorganisms growing as sessile communities in a large number of human infections has been extensively studied and recognized for 30–40 years, therefore warranting intense scientific and medical research. Nonetheless, mimicking the biofilm-life style of bacteria and biofilm-related infections has been an arduous task. Models used to study biofilms range from simple in vitro to complex in vivo models of tissues or device-related infections. These different models have progressively contributed to the current knowledge of biofilm physiology within the host context. While far from a complete understanding of the multiple elements controlling the dynamic interactions between the host and biofilms, we are nowadays witnessing the emergence of promising preventive or curative strategies to fight biofilm-related infections. This review undertakes a comprehensive analysis of the literature from a historic perspective commenting on the contribution of the different models and discussing future venues and new approaches that can be merged with more traditional techniques in order to model biofilm-infections and efficiently fight them.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

1Pioneer studies by A.T. Henrici in the early 20th century and later by J. W. Costerton and colleagues have pointed to the existence of microorganism populations living on surfaces. Nowadays it is well accepted that, in most environments, microorganisms can switch from a free-living state to a sessile mode of life to form biofilms displaying specific properties. Among these specific properties is an enhanced tolerance to all sort of adverse conditions including desiccation and high concentrations of antimicrobial agents such as biocides, antibiotic and antifungal compounds. Microorganisms growing and persisting on surfaces are problematic because, on one hand, they represent a source of contamination when present in a closed hospital environment and, on the other hand, when introduced into the body, they can develop on medical devices or tissues such as mucosa to form antimicrobial tolerant biofilms. N. Hoiby, J.W. Costerton and their collaborators were the first to suspect a direct correlation between bacteria growing as communities and persistent infections notably in the case of Pseudomonas aeruginosa colonizing the lungs of cystic fibrosis patients. Since then, an increased awareness of the link between microorganisms growing on surfaces and development of human infections led to the estimation that 65% (Centers for Disease Control and Prevention/CDC) to 80% (NIH) of human infections were associated with biofilms (Figure 1). While difficult to precisely evaluate, such estimates reveal the importance of studying biofilms in order to better understand their specific properties and fight them.

2Development of simplified models started right after the demonstration of a link between sessile communities and human infections to study how bacteria, including pathogens, can form biofilms. Multiple in vitro models have emerged from scientists’ creativity, each of them especially adapted to observe biofilm formation of specific bacteria and within specific environments. The success of in vitro models but also their limitations, notably their failure to reproduce the host environment, led to a rapid development of multiple in vivo models ranging from surrogate non-mammalian models allowing high throughput analysis to more sophisticated models using rodents or higher animals such as dogs, pigs and monkeys. Interestingly, many of these models have been developed before clinicians and researchers realized that the modeled infection was indeed biofilm-related. Importantly, because of justified ethical concerns, the use of mammalian in vivo models was early on restricted by legal regulations implying evaluation of scientific and medical benefits of the research but also taking into account animal welfare. The protection of vertebrate animals therefore entails the evaluation of each project by ethics committees to confirm that they follow the “three R rule” edicted by Russel and Burch in 1959: Replace, Reduce and Refine. This partially explains why in vitro and in vivo surrogate non-mammalian models are still heavily used and continue to reveal important insights about biofilm physiology and promising treatments for biofilm-related infections.

3The aim of this review is to present the various aspects of the development of biofilm-related infection models ranging from simple in vitro to complex in vivo models. We will focus on discussing which experimental results have already or are about to reach clinical studies in humans. This review will also discuss specific future approaches that start to be used and should help to model better biofilm-related infections.

2. In vitro Biofilm Models

4Simplified in vitro models have been instrumental in addressing basic questions about biofilm formation, physiology and architecture. They offer a number of advantages such as a low cost, easy set-up, and amenability to high throughput screens. They generally mimic hallmarks of biofilm biology like different gradients of nutrients, gases and metabolic products, as well as high cell densities or production and release of extracellular matrix.

5A complete and comprehensive list of in vitro biofilm models is provided in Table 1 and see for further information. Briefly, the different in vitro biofilm models can be classified in three distinct groups: Closed or static models, in which there are limited nutrients and aeration. This includes some of the most popular and successful models, such as the colony biofilm model and microtiter plates. In addition, these models enable direct rapid quantification of biofilm mass (via stains like crystal violet, safranin and congo red) or viable cells (XTT reduction assay).Open or dynamic systems. The principle of these models is similar to continuous cultures, in which spent culture consisting of wastes, metabolic byproducts, dispersed and dead cells are constantly replaced by fresh medium. These methods generally allow the control of environmental parameters such as shear forces, and have been therefore extensively used to study the physical and chemical resistance of biofilms. However, they are in most instances less adapted to high throughput analysis and often demand specialized equipment and technical skills.Microcosms are more sophisticated models that aim to closely mimic in situ conditions. They often include several bacterial species and use material from the studied environment, for instance, addition of hydroxyapatite and saliva to model dental biofilms, or covering abiotic surfaces with human cells in order to mimic an in vivo situation. Theoretically, both open and closed systems could be turned into microcosms. Microcosms include more environmental parameters and take into consideration the complexity and heterogeneity of natural settings.

6Closed or static models, in which there are limited nutrients and aeration. This includes some of the most popular and successful models, such as the colony biofilm model and microtiter plates. In addition, these models enable direct rapid quantification of biofilm mass (via stains like crystal violet, safranin and congo red) or viable cells (XTT reduction assay).

7Open or dynamic systems. The principle of these models is similar to continuous cultures, in which spent culture consisting of wastes, metabolic byproducts, dispersed and dead cells are constantly replaced by fresh medium. These methods generally allow the control of environmental parameters such as shear forces, and have been therefore extensively used to study the physical and chemical resistance of biofilms. However, they are in most instances less adapted to high throughput analysis and often demand specialized equipment and technical skills.

8Microcosms are more sophisticated models that aim to closely mimic in situ conditions. They often include several bacterial species and use material from the studied environment, for instance, addition of hydroxyapatite and saliva to model dental biofilms, or covering abiotic surfaces with human cells in order to mimic an in vivo situation. Theoretically, both open and closed systems could be turned into microcosms. Microcosms include more environmental parameters and take into consideration the complexity and heterogeneity of natural settings.

9Although often regarded as over-simplistic, in vitro models have greatly contributed to today’s knowledge of biofilm physiology. They are still largely used to study the role of different genes involved in biofilm formation and regulation processes, as well as other applied purposes such as to screen libraries of antimicrobial agents. Nevertheless, these models ignore important parameters like environmental factors, or more specifically when characterizing pathogenic biofilms, host factors and other biotic signals.

3. Ex vivo Biofilm Models

10Midway between in vitro and in vivo lie ex vivo models, in which tissues or organs are extracted from an organism (typically porcine or murine) and placed in an artificial environment for further analysis and experimentation. Often neglected, they allow for more controlled experimental conditions than in vivo models and can provide an alternative to living organisms in order to perform otherwise ethically questionable measurements and experiments. They can be particularly useful to image or analyze the progression of bacterial colonization of a given organ or tissue, such as tracheal epithelium, vaginal mucosa, kidneys or teeth. They can also be used to assess different time-windows for effective treatment of biofilm infections. Details of different ex vivo models are described in Table 1.

4. Non-Mammalian in vivo Models

11Infection and pathogenesis is a continuous interplay between the host and microbes and between microbes themselves. These interactions can influence and determine the fate of infection and they are complex and dynamic, which makes it difficult to study them in a relevant manner in in vitro models. As in vitro models offer a simplified vision of the environment, it is important to use adequate in vivo models to validate in vitro results as a first step to test hypothesis that could be later translated into higher organisms or clinical settings.

12In the past ten years, in order to overcome the practical difficulty associated with the use of mammalian models, non-mammalian models traditionally used to study development like the fruit fly, Drosophila melanogaster or the zebrafish, Danio rerio, have been adapted to study host-microbe interactions and immune system responses, notably related to colonization of the gut by biofilms. Increasing awareness of biofilm-related infections has prompted these and other models discussed in Table 2 and Figure 2, to study tissue colonization, biofilm formation and the onset of pathogenesis. Many different models have been proposed, ranging from simple plant models such as Arabidopsis thaliana and Lemna minor, which were successfully used to correlate virulence and biofilm formation in pathogenic S. aureus and P. aeruginosa to more complex invertebrates like Caenorhabditis elegans, D. melanogaster (Figure 2) or the vertebrate zebrafish (Table 2 and Figure 2).

13Non-mammalian models share advantages such as a rapid development leading to short generation time and are generally cheap to raise and perform experiments. In addition, most of these model organisms have their genome already sequenced and can be genetically manipulated, thus, offering the possibility to do genetics both on the bacteria and the host. In addition, their small size enables to maintain most of them in microtiter plates, which is useful to perform high throughput studies, some of which in an automated version. This has already allowed successful screening for virulence genes, colonization and biofilm formation factors or chemical libraries for antimicrobial compounds.

14Their reduced complexity for some pivotal systems linked to infection has actually been an advantage. For example, despite the simplicity of their immune system, these surrogate non-mammalian organisms have been useful to identify evolutionarily conserved host defense mechanisms and have shed light into universal immune mechanisms. Additionally, the facility of generating axenic or gnotobiotic animal models has allowed simplifying host/pathogens and flora interactions studies. Recent research using an axenic zebrafish model has proven that increased biofilm forming ability of commensal bacteria can rescue larvae from Edwardsiella ictaluri-induced death.

15Nevertheless, these models reached their limits when studying complex immune responses in relation to biofilm infection or using pathogens whose optimal growth temperature and expression of virulence factors are beyond the animal growth temperature. Moreover, due to the short lifespan and duration of experiments, these models seem unsuited to study chronic infections typically caused by biofilms.

5. Tissue-Associated Biofilm Models

16While important information has been generated using in vitro and invertebrate in vivo models, the use of mammalian models that are closer to humans is required before considering going from bench to bedside. Therefore, many efforts have been made to closely mimic in higher organisms the occurrence of biofilm-related infections that allowed us to address diagnostic or therapeutic challenges (see Table 3).

17The role of biofilm in the pathophysiology of tissue-associated infection has been increasingly recognized in the past decades (Figure 1). Biofilm may develop after colonization of sterile or non-sterile tissue or mucosa by microorganisms or may take advantage of the prior alteration of resident commensal flora by antibiotics.

5.1.1. Cystic Fibrosis (CF) Related Lung Infections

18CF disease is the result of a single gene mutation in cystic fibrosis transmembrane conductance regulator (CFTR) leading to a multitude of medical problems amongst which are pancreatic failures, alteration of mucosal secretions and of epithelial innate immune function in the lungs. However, the most challenging aspect of the disease is pulmonary infection that leads to 80–95% of respiratory failure by chronic bacterial infection and airway inflammation. While previously suggested by Lam et al. and Hoiby et al., who showed the presence of matrix-embedded microcolonies of P. aeruginosa in chronically infected lungs, confirmation of the role of biofilms was provided by Singh et al., through identification of a specific quorum sensing signal signature.

19Animal models used to mimic CF infected lungs can be broadly divided based on the route of infection chosen: intratracheal or intravenous.

20Intratracheal route: Cash et al., were the first to describe a rat model to establish P. aeruginosa chronic lung infection, lasting up to 1 month, by immobilizing bacteria in agar beads. This model was later adapted to mice, guinea pigs, cats, monkeys and to other pathogenic agents like S. aureus, Burkholderia cenocepacia and Haemophilus influenzae. This model depicts human clinical pathologies such as bacterial persistence and airway inflammation. Amongst very recent uses, it successfully evaluated the efficacy of liposomal bismuth-ethanediol loaded tobramycin against P. aeruginosa infection in rat lungs. Another rat model developed by Pedersen et al., used bacteria embedded in seaweed alginate microspheres. Amongst other advances, this model showed the role of Psl and Pel polysaccharides as a scaffold of biofilms formed by mucoid P. aeruginosa phenotype biofilms in mice. In addition, to study pharmacokinetics/dynamics of colistin and imipenem, a neutropenic mouse model of lung biofilm infection was developed.

21Intravenous route: Developed by Sawai et al., this model also makes use of pathogens embedded in agar beads, which are afterwards injected intravenously to mice. Efficiency of several antimicrobials, such as linezolid, quinolones and carbapenems was assessed using this model.

22A relevant infection model of CF should reflect human lung infection characteristics such as airway inflammation and spontaneous bacterial infection progressing to chronic stage with characteristic biofilm formation. An attempt to achieve this was made in 1992 with a CFTR knock out mouse. Though mice did not show spontaneous lung disease, airways inflammation and chronic infection were established, and this model was successfully used to model chronic P. aeruginosa lung infections using agar beads and to evaluate the efficacy of azithromycin against P. aeruginosa biofilms. The CFTR knockout mice provided important information on the molecular mechanisms explaining the efficacy of azithromycin in clinical trials. Recently, this model was also used to mimic lung co-infections by P. aeruginosa and B. cenocepacia. CFTR knockouts were later translated into pigs (ΔF508/ΔF508) and ferrets. They were used to study S. aureus pathogenesis in CF and general CF pathology, respectively.

5.1.2. Other Lung Conditions

23Chronic obstructive pulmonary disease (COPD) related lung infections: COPD is a progressive lung disease characterized by emphysema, chronic bronchitis and bronchiectasis. The etiological agents of COPD-related airways infection include non-typeable H. influenzae (NTHi), Streptococcus pneumoniae, Moraxella catarrhalis and P. aeruginosa. So far, only one mouse model of COPD-NTHi lung infection has been reported and allowed to demonstrate the presence of persistent multicellular bacterial communities in elastase-damaged lungs and the role of CD54 in NTHi clearance.

24Diffuse panbronchiolitis (DPB): DPB is characterized by thickening of bronchiolar walls and is commonly associated with accumulation of lymphocytes, plasma cell and histiocytes. There is large evidence involving bacterial biofilms in DPB. To mimic chronic P. aeruginosa DPB infection in the respiratory tract, a murine model was developed in which a small piece of intravenous catheter (tube) precoated with P. aeruginosa was inserted into the mouse trachea. This model was used to study the efficacy of macrolides against chronic in vivo P. aeruginosa infections and the role of inflammatory cytokines and dendritic cells in pathogenesis of DPB.

5.2. Urinary Tract Infection (UTI)

25Urinary tract infections, which include infection of bladder (cystitis) and kidneys (pyelonephritis associated with or without kidney stones) primarily affect women and account for nearly 13 million annual doctor’s visits in the United States alone. Recurrence of UTI is a major concern with 20–30% incidences among adult women. However, elderly and prepubertal children are also susceptible to recurrent and chronic cystitis. Etiology of UTI is dependent on host genetics, biological and behavioral factors and has been largely associated with presence of Escherichia coli (E. coli) (80% cases) and to a lesser extent to Staphylococcus saprophyticus (10–15%) followed by Klebsiella, Enterobacter, Proteus and Enterococcus species.

5.2.1. Cystitis

26Bacterial colonization of the bladder results in a mucosal inflammatory response called cystitis. Uropathogenic E. coli (UPEC) are the most widely studied bacteria. Except for few studies using rats where preventive effect of fosfomycin trometamol (FOF) was evaluated against chronic cystitis, most information on UTI originated from mouse models. In addition to genome availability and repertoire of knockout mutants, mice are naturally susceptible to UPEC strains and experimental infection closely resembles human disease. Mouse model of cystitis was efficiently used to demonstrate that uropathogenic strains of E. coli and K. pneumoniae exist in biofilm-like large aggregates of bacteria (pods or intracellular bacterial communities, IBC) in the bladder epithelial cells suggesting one possible mechanism of recurrent cystitis. These pod-like structures were later shown to exist in human bladder during UTI. Murine pod like structures exhibited resistance to antibiotics and host system and were protected against trimethoprim sulfamethoxazole. This model has been successfully used to study the molecular mechanisms involved in IBC formation and virulence of UPEC such as role two-component system QseBC, importance of peptide transport, TCA cycle and gluconeogenesis but not glycolysis. Importantly, this model also highlighted the role of type 1 pilus and its associated tip adhesin, FimH, in IBC formation. Type 1 fimbriae were shown to mediate adherence and invasion of urothelial cells via FimH affinity for mannosylated urothelium proteins such as uroplakin. Consistent with the instrumental role of FimH in UPEC bladder colonization, vaccines against FimH as well as FimH specific inhibitors were later shown to be protective or efficient against established infection in murine and/or primate models of acute cystitis. These anti-FimH strategies are very promising and clinical studies proving their efficacies are now expected. Other prophylactic or curative strategies based on bacterial interference and immune system stimulation with non-adherent asymptomatic bacteriuria strain 83972 were successfully assessed using UTI mouse models and validated in patients.

27Murine studies have also been extensively carried out to confirm the role of innate immune responses in disease outcome and recurrence and highlighted the importance of TLR4 signaling. Furthermore, CD8+ T cells were reported to play a role in adaptive response to UPEC bladder infections. Murine UTI model led to identification of biomarkers associated with chronic cystitis including elevated serum IL-5 and urine IL-6, G-CSF (Csf2) and KC (CXCL1) and more recently the autophagy gene Atg16L1 was shown to play an important role in pathogenesis of UTI.

5.2.2. Chronic Bacterial Prostatitis (CBP)

28CBP is a persistent inflammation of the prostrate glands due to bacterial invasion. CBP may account for 5–10% of total prostatitis pathology. First evidence of biofilms from biopsied prostatic tissues confirmed the presence of sparse microcolonies of S. aureus in the prostatic duct walls. The major causative agents are from the Enterobacteriaceae family, like E. coli but also Enterococcus faecalis, Pseudomonads, Staphylococcus species and gonococcal organisms. The capacity of these bacteria to form biofilms containing antibiotic persistent bacteria explains recurrent CBP. The rat model has been extensively used to demonstrate the importance of virulence factors or quorum sensing systems in CBP. This model was also used to evaluate therapeutic strategies against E. coli-induced CBP using catechin, ciprofloxacin, or cranberry as well as the potential of selenium in combination with ciprofloxacin.

5.2.3. Other UTI

29Infectious urinary stones/calculi or Struvites: Persistent infections caused by urease producing bacteria may lead to rapidly growing infectious stones within 4–6 weeks. Initial clues of biofilm involvement in infectious stones date back to 1971 when Nemoy et al., showed the presence of antibiotic resistant bacteria embedded in stone resulted in recurrent urinary infections. The first hypothesis that such antibiotic resistance was due to bacteria growing within glycocalyx matrix of biofilms was later confirmed by scanning electron microscopy and transmission electron microscopy. The most common urease producers involved in infectious stones are: Proteus spp., Ureaplasma spp., Pseudomonas spp., Klebsiella spp., and Staphylococcus species. Moreover, Oxalobacter formigenes and Lactobacillus were also suggested to cause nephrolithiasis. Rat is the most widely utilized animal to develop experimental infectious stones and most of the studies were performed with Proteus mirabilis and Ureaplasma urealyticum. Using a foreign body such as zinc or chalk to develop bladder stones helped understanding the kinetics of stone formation and the role of P. mirabilis biofilms in this process. This type of infectious urolithiasis rat model was also used to study therapeutic strategies against polymicrobial (P. mirabilis, P. aeruginosa and E. faecalis) stone infection.

30Pyelonephritis: Once bacteria enter the kidney, they adhere to the urothelium and papillae to form biofilm-like structures. While numerous models of acute pyelonephritis have been developed, the presence of biofilms was demonstrated solely for P. mirabilis biofilms on the rat urothelium.

5.3.1. Intestinal Infections

31The human gastrointestinal tract is covered by a biofilm of commensal bacteria that form independent communities depending on the colonized niches. Similarly, biofilms were shown to colonize the mucus layers of large intestine of other animals such as baboons, rats and mice. The gut biofilm is shaped by different factors, both environmental and specific to the host. Alterations of the flora equilibrium might lead directly to pathology, altered physiological and immunological states due to changes in the functional microbial core. Gut diseases can be separated in two groups: acute diseases such as diarrhea that are generally due to a pathogenic bacteria displacing the commensal flora and impacting directly on intestinal epithelial cells, and chronic diseases such as inflammatory bowel disease, commonly named IBD, a group of inflammatory conditions of the colon and the small intestine that can evolve to colorectal cancer and that have been partly linked with a microbial imbalance of the gut commensal flora (dysbiosis). The streptomycin-treated mouse model of intestinal colonization developed long ago has been extensively used to study both virulence factors and hosts components involved in intestinal colonization (see for example). In addition, infectious colitis models of gnotobiotic mice or conventional mice colonized by their natural pathogens such as Citrobacter rodentium have been used.

5.3.2. Gall Bladder Infections

32Salmonella enterica serovar Typhi is the causal organism of typhoid fever and is amongst the best-studied gut bacteria. Inability of antibiotics to resolve the Salmonella Typhi colonization of the gall bladder indicated the role biofilm in this chronic disease. A mouse model of chronic Salmonella infections was developed by Sukupolvi S et al. and was later used to analyze chronic infections that persisted for 1 year following oral infection. Crawford RW et al., (2010) recently developed another mouse model of enhanced S. Typhimurium colonization of gall bladder tissue, which allowed visualization through electron microscopy of a dense biofilm covering more than 50% of gallstone surface.

5.4. Wounds Infections

33Despite the controversial role of biofilms in delayed wound healing, it is now well accepted that wounds are colonized by biofilms as confirmed by SEM and other molecular techniques. The most commonly studied microorganisms associated with wounds infections are S. aureus and P. aeruginosa. Several animal models of traumatic wounds including skin abrasions, burns, lacerations, surgical and excisional wounds or open fractures have been published. Dai et al., developed a needle scratch mouse model in which they used genetically engineered bioluminescent S. aureus to study biofilm formation and the use of photodynamic therapy. Several burn models have been developed, amongst which is a mouse model that allowed the visualization of P. aeruginosa biofilms infection in a third degree lesion using PNA-FISH (Figure 3).

34Besides, other animal models were developed to study the involvement of different bacteria, such as S. aureus, S. epidermidis, P. aeruginosa and E. coli in excisional wound infections and allowed to (i) show the infiltration of inflammatory cells within S. aureus clusters, (ii) confirm the presence of “membrane like structures” by electron microscopy (iii) reveal the important role neutrophils play in host defense and (iv) assess bacterial susceptibility to antibiotic therapy. In addition, a cutaneous porcine wound model allowed the evaluation of topical antimicrobial treatment of S. aureus biofilms. In vivo murine models also allowed deciphering the effect of RNAIII-inhibiting peptide (RIP, a quorum sensing inhibitor) in combination with teicoplanin against methicillin-resistant S. aureus and to directly correlate P. aeruginosa autoinducer with tissue destruction and inflammatory response using pressure-induced ischemic wound model in rats. Diabetic patients are especially prone to develop problematic wound infections that are colonized by several species of microbes forming complex multispecies biofilms of up to 1600 different microorganisms. Although animal models are scarce, a leptin receptor-deficient mice model was developed to study synergistic effects between E. coli, Bacteroides fragilis and Clostridium perfringens in type 2 diabetes foot wounds.

5.5. Endocarditis

35In the early 70s, in order to study infective endocarditis (IE), or the infection of heart inner lining, experimental models using rabbits, rats, pigs and cats were developed. However, the fact that progression of IE is due to biofilm establishment was demonstrated in the early 2000s. Although, several microorganims have been associated with IE, including streptococci, staphylococci, and Candida, S. aureus is the major cause of endocarditis and thus, has been extensively studied in experimental IE. Rabbit endocarditis model has been used to decipher genetics of S. aureus biofilms in vivo, for instance, the positive modulation of the alpha-toxin gene (hla) by agr, sarA and sae, three major S. aureus global regulators. In addition, the rabbit model allowed the study of streptococcal endocarditis confirming the presence of a biofilm structure by electron microscopy (Figure 4). A rat model of IE was also developed wherein endocarditis was induced by continuous low-grade bacteremia mimicking spontaneous bacteremia in humans. This model was later used to highlight the role of S. aureus adhesion to fibrinogen and fibronectin, as well as platelet aggregation, in the initiation of in vivo IE. Several other animal studies have been performed to evaluate the efficiency of single or combination therapies against IE with oritavancin, vancomycin, gentamicin, daptomycin or ceftobiprole.

5.6.1. Chronic Otitis Media (OM)

36OM is the infection of middle ear leading to inflammation and is one of the most common diseases affecting children. First evidence of biofilm involvement was confirmed by direct detection in mucosa samples recovered from middle ears of children with chronic and recurrent OM. Three major pathogenic agents of OM, S. pneumoniae, nontypeable H. influenzae (NTHI) and M. catarrhalis formed biofilms in vivo. The most commonly used models for OM are chinchilla, mouse and rats. The first chinchilla model was developed in 1976 using S. pneumoniae and was later used to study pathogenesis, immune response, efficacy of antimicrobials against S. pneumoniae and vaccine candidates. Chinchilla has several advantages such as long life span of 15 years, strong ear anatomical similarity to humans, intact organ systems and immune functions, presence of large cephaloid bulla that make sampling easier and sufficient. Moreover, this model enables direct visualization of biofilm development on the middle ear mucosa by CLSM. Amongst other reports, this model showed that group A streptococcus (GAS) biofilms are inhibited in absence of virulence regulator Srv and that c-di-GMP improves persistence of P. aeruginosa biofilms in chronic supportive OM.

37Murine models of OM have also contributed to better understanding virulence factors, bacterial adhesion, invasion mechanisms, and general or specific inflammatory responses. For instance, the use of Swiss-webster mice highlighted the role of pneumococcal proteins PavA, UspA or (Usp) A2 in adhesion.

38In order to study long-term chronic OM, several models were adapted, for example, the primate model in cyanomolgus macaques to study the P. aeruginosa biofilms, a rat model that allowed follow up of S. pneumoniae up to 7 months or plasminogen (plg)-deficient mice to study spontaneous development of chronic OM with varying inflammatory responses over a period of 18 weeks.

5.6.2. Chronic Rhinosinusitis (CRS)

39Chronic rhinosinusitis is the inflammation of paranasal sinuses, mainly due to bacterial invasion, typically of S. aureus, CoNS (coagulase negative staphylococci), P. aeruginosa, S. pneumoniae or H. influenzae. Several clinical studies demonstrated biofilm morphology in mucous samples from human CRS. The most common CRS model is rabbit which allows animals monitoring up to 9 months for signs of inflammation but mouse and sheep models have also been developed.

5.7. Dental Biofilms

40Dental plaque is one of the most common types of polymicrobial biofilms that develop on susceptible tooth surfaces.

5.7.1. Dental Caries

41The main factors governing the virulence of the dental caries pathogenicity are extracellular polysaccharide (EPS) matrix and acidified plaque milieu. Several models have been developed to study the cariogenic biofilms, amongst which, the most widely used is the rodent model of cariogenesis using streptococci. It has enabled us to define the infectious character of the disease, role of different genes in cariogenic process and the effect of salivary proteins in plaque formation. Topical administration of bacteria to study dental plaques has been carried out in Sprague Dawley rats and there is evidence of different outcomes in host response depending on genetic background of rats. Furthermore, this model has been used to evaluate antimicrobials against dental plaques.

5.7.2. Periodontitis

42Periodontitis, or destruction of periodontium structure, is due to the presence of pathogenic biofilms on the gingival and periodontal tissues resulting in heightened inflammatory response. It involves both innate and acquired immunity. The major pathogens causing supra and subgingival biofilms are Gram-negative anaerobes such as Porphyromonas gingivalis, Treponema denticola and Tannerella forsythia, referred to in humans as “red complex”. Many models of periodontitis have been developed using primates, dogs, rodents, rabbits, pigs and ferrets. Nevertheless, the use of superior mammals has ethical, handling, housing and expense related issues. Thus, their use should be confined to preclinical studies. Rodents have dental gingival area similar to humans, and periodontitis disease was also shown to induce bone loss in these animals. Hence, use of rodents is relevant to study microbiological and immunological aspects associated with periodontitis. For example, it has been shown that T. denticola persisted in a mice gavage model up to 71 days and significantly reduced IL10 whereas P. gingivalis could be detected up to 11 weeks with migration of monocytes and neutrophils in gingival connective tissues. Several studies in rodents have also addressed synergistic effects of such polymicrobial infections in periodontitis outcome. Finally, an experimental rabbit model was used to evaluate efficiency of different anti-inflammatory molecules and antimicrobials such as resolvins, protectins, lipoxins in periodontitis induced by P. gingivalis.

5.8.1. Osteomyelitis

43Osteomyelitis, or the infection of the bones or bone marrow, is a frequent complication associated with open fractures. Direct scanning electron microscopy confirmed the presence of bacterial biofilms in osteomyelitic bone samples. Since the first study in 1941 of S. aureus chronic osteomyelitis in tibia, the rabbit model has been widely used to study chronic bone infection. This has allowed to identify proteins involved in S. aureus biofilm development in bones, and to evaluate the effect of various antimicrobials. In another study, an experimental rat model of MRSA osteomyelitis was used to demonstrate the superiority of fosfomycin over daptomycin in treating osteomyelitis. More recently, a non-invasive mouse model using bioluminescence allowed monitoring of chronic femur S. aureus infection up to 21 days.

6. In vivo Models of Device-Related Infections

44The first evidence of the involvement of biofilm in device-related infections was provided in 1982 with electron microscopy study of a pacemaker implanted in a patient with recurrent S. aureus bloodstream infection. Since then, almost all types of indwelling devices have been associated with the occurrence of bacterial or fungal biofilms (Figure 1). Because of a high tolerance towards antibiotics, these device-related infections are difficult to treat and expose patients to the risk of recurrence. As the role of biofilm has been increasingly recognized, many in vivo models of device-related infections have been developed to validate in vitro data regarding mechanisticquestions, as well as to assess the preventive or curative approaches specifically targeting biofilm lifestyles (Table 3).

45In vivo models of device-related infections can be broadly divided in two groups. On the one hand, the foreign-body is inserted in the organ or in the same position as it is used in clinics. Examples of these “site-specific models” are intravascular catheter models or intrafemoral pins or wires. On the other hand, the foreign-body is inserted in a subcutaneous pocket so that there is no contact with a specific structure or organ, therefore defining the “subcutaneous models” such as tissue cage model or subcutaneously inserted pieces of catheters.

6.1.1. Vascular Catheters

46During an outbreak of catheter-related infections, the observation that S. epidermidis was able to produce extracellular matrix (in the past called “slime”) and adhere to surfaces identified the importance of biofilm in this setting. First attempts to set-up in vivo models relied on the subcutaneous implantation of catheter cut in pieces (see the “subcutaneous models” section). Even though this approach helped understanding mechanisms involved in S. epidermidis biofilm formation, these models lacked several important features of catheter-related infections such as interaction with blood components or blood flow. These limitations led to considerable efforts to develop in vivo models integrating these aspects.

47The most popular intravascular venous catheter model developed to study bacterial colonization and subsequent infection was described in 1999 using a silastic catheter inserted into the superior vena cava of adult rats. The rat model has been used to validate the in vivo importance of polysaccharide intercellular adhesin (PIA) and autolysin AtlE in the establishment of a S. epidermidis biofilm and in its pathogenesis (bloodstream infection and metastatic disease). This model allowed assessing preventive approaches, such as use of RNAIII-inhibiting peptide (RIP) or vaccination with immunization of rats prior to catheter insertion leading to a protective effect towards bacterial colonization of the device by S. aureus or S. epidermidis. Other animals such as rabbits or mice have also been used to develop such central venous catheter (CVC) models with similar surgical procedures.

48Attempts to eradicate in vivo biofilms have been made using antibiotic lock technique/therapy (ALT). In this treatment, a highly concentrated antibiotic solution is allowed to dwell for 12 to 24 hours inside the lumen of a catheter. Conclusions of the different studies are difficult to compare as different authors used various compounds, concentrations and time of treatment. It was demonstrated that against S. aureus, quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin dwelling for 1 hour were able to reduce the amount of survival CFU in blood and on catheter tip but none of them eradicated biofilm, suggesting the importance of a longer dwelling time. ALT composed of daptomycin associated with systemic treatment was also assessed in order to eradicate S. aureus and S. epidermidis catheter-related infections using polyurethane CVC: vancomycin and daptomycin were equally efficient against methicillin-resistant S. epidermidis (MRSE) infection. A rabbit CVC model allowed researchers to demonstrate that heparin had no effect and that it did not improve the efficacy of vancomycin or ciprofloxacin ALT on S. aureus biofilm. Later, the same group compared linezolid, vancomycin, gentamicin and ciprofloxacin antibiotic solutions as ALT against S. aureus biofilm. In this model, gentamicin (40 mg/mL) was the most efficient drug against methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). In addition, association of minocycline-EDTA as lock therapy has been shown to efficiently reduce the number of rabbits with positive blood cultures and in eradicating biofilm on the catheter tip. All these data have been used to design clinical studies and some of these compounds are now used in clinics.

49Recently, we developed an in vivo model of totally implantable venous access port (TIVAP)-related infection to study long-term biofilms (Figure 5). TIVAPs are used for antineoplastic chemotherapy, parenteral nutrition or blood products in humans. These devices are composed of a vascular catheter inserted into the external jugular vein of a rat connected to subcutaneous port. This model does not require the use of a restraint jacket and use of bioluminescent strains allows long-term non-invasive monitoring of biofilm formation. We used this model to demonstrate the ability of an association of gentamicin and tetrasodium EDTA to eradicate 3-day old biofilm of S. epidermidis, S. aureus (MRSA or MSSA), P. aeruginosa and E. coli. A clinical study can now be set-up, based on these data.

6.1.2. Urinary Catheters

50The observation that systemic antibiotic failed to eradicate bacteriuria without removal of the urinary tract device was made decades ago. In 1985, the electron microscopic study of a urethral catheter removed due to relapsing catheter associated urinary tract infection (CAUTI) revealed the presence of a bacterial biofilm. Since then, many in vivo models have been developed in order to mimic these situations. Most of them rely on the insertion of a foreign-body inside the bladder and may or may not include a surgical procedure. Therefore, urinary catheter-associated models can be classified in 3 groups: (i) and (ii) foreign-body left inside the bladder with or without a surgical procedure; (iii) a complete urinary catheter with a tip located inside the bladder, associated with a urine collection system and exiting through urethra.

51(i) Surgical models. These models rely on the surgical insertion of a foreign-body inside an animal bladder such as glass beads or pieces of urinary catheter. They allowed the study the effect of persistent bladder colonization on renal scaring but also to assess different therapeutic strategies. First develop in rats, the same model was later adapted in mice to demonstrate the use of mannitol as an adjuvant to gentamicin to eradicate biofilm persisters of E. coli, which can be a promising clinical candidate.

52(ii) Non-surgical models. The principle of these models is to transurethrally insert pieces of catheter inside the animal bladder. These models have been developed in rats, rabbits and mice to study several aspects of CAUTI such as bladder inflammation, virulence of E. faecalis on a silicone implant or preventive approaches such as Triclosan® (a broad spectrum antiseptic). Various curative treatments have been assessed in these models, such as antibiotics alone or in the association with small molecules (like mannosides) to prevent CAUTI. This adjuvant approach still needs to be validated in clinic.

53(iii) Models of externalized urinary catheters. In order to mimic a complete urinary catheter with an externalized system, urethral models were developed in rabbits and sheep and used to study the effect of systemic antibiotics on viable cell count or biofilm structure on the catheter tip. Preventive approaches have also been assessed such as antiseptic-coated catheters like Gendine or Low-Energy Surface Acoustic Waves. Another approach was developed using a sheep model to study iontophoresis as a preventive measure. In this model, urethral catheters are modified in order to deliver a current to electrodes located on the catheter tip leading to the production of ions of soluble salts and allowing the formation of local biocide. After 20 to 21 days, this approach significantly reduced bacterial burden in urine.

54Even though all these models identified promising compounds, clinical studies remain rare or gave negative results such as a recent clinical study using antibiotic-coated catheters without any significant clinical benefit.

6.1.3. Orthopedic Implants and Prosthetic Joints

55First reported work trying to reproduce osteomyelitis in rabbits was published as early as 1885. In early 70’s, it was shown that the presence of a foreign-body inserted into a rabbit tibia (stainless steel pin) could potentiate the development of chronic S. aureus osteomyelitis. Interestingly, it is only ten years later that the link between biofilm formation and orthopedic devices was confirmed in clinics and using a rabbit model of foreign-body inserted inside the tibia. Even though rabbits have been frequently used for these studies, orthopedic implant models have been developed in many other animals with a wide range of foreign-bodies and sites of insertion (see Table 3). These models allowed the study of the influence of various types of materials such as stainless steel, titanium, cobalt chromium, polyethylene or polymethylmetacrylate on bacterial adhesion. It has also been demonstrated that bone devascularization, presence of foreign-body and bacterial virulence played a key role in the incidence of osteomyelitis. Moreover, the impact of adaptive immune responses was studied to show that Th2/Treg responses played a key protective role against chronic S. aureus implant infection. Besides, preventive approaches have been assessed, such as use of gentamicin for systemic and local treatment or as a coating of the device. Lastly, different models have been developed to study antibiotic-impregnated cement or implants. Promising results were obtained using gentamicin-coated nails in the tibia in a clinical pilot study.

56Even though osteomyelitis and prosthetic joint infections (PJI) share common features, different animal models have been developed in order to assess specific characteristics of PJI. These models allowed to study diagnostic procedures such as magnetic resonance imaging (MRI) modification after S. aureus PJI as well as preventive approaches like gentamicin-loaded bone cement for prevention of E. coli PJI or prevention of S. aureus PJI after bloodstream infection. Another preventive approach relying on a minocycline/rifampin-impregnated bioresorbable polymer implant coating has been shown to reduce biofilm formation. Another key contribution of these models is the study of distribution and efficacy of frequently used antibiotics such as fluoroquinolones.

6.1.4. Endotracheal Tubes

57Biofilm formation in endotracheal tubes was described in 1989 and it is now considered that they can constitute a potential source of ventilator-associated pneumonia (VAP) that can escape antibiotics in case of systemic treatment. Animal models using sheep, pigs or dogs have been developed. They rely on the orotracheal intubation of animals with endotracheal tubes and mechanical ventilation for 24 to 96 hours and have been used to study preventive or curative strategies (see Figure 6). These models have, for example, been used to demonstrate the effectiveness of endotracheal tubes coated with silver-sulfadiazine/chlorhexidine in polyurethane or silver hydrogel coating to reduce bacterial colonization. These data enabled the performance of a clinical study demonstrating that this approach significantly reduced the incidence of VAP in clinics. This model was later used to show that a mechanical removal of biofilm from the surface of endotracheal tubes prolonged the bactericidal activity of such coated devices. This approach called “mucus shaver” allows the retention of the device in place and biofilm removal from its surface. This mucus shaver procedure was assessed in a pilot study including 12 patients in each group and allowed a significant reduction of the number of endotracheal tubes colonized with biofilm.

6.1.5. Vascular Grafts

58Identification of involvement of biofilm in the occurrence of vascular graft-related infection was made at the end of the 80’s. Such graft-related infection was later studied in a dog model to develop diagnostic or surgical procedures. This model relied on the implantation of dacron prosthesis colonized by S. epidermidis on the infrarenal aorta of a dog leading to the development of a prosthetic vascular graft infection (PVGI). This model was notably used to study the effectiveness of rifampicin-bonded gelatin-impregnated grafts in reducing the number of animals with persistent biofilm colonization. Another group confirmed that rifampicin-soaked silver-coated polyester (RSSCP) was more efficient than expanded polytetrafluoroethylene (ePTFE) graft replacements, in the treatment of aortic PVGI porcine model. This model was also adapted in miniature pigs to demonstrate that Dacron graft bonded with chlorhexidine, rifampicin, and minocycline was a good candidate for the prevention of S. aureus related infections. First clinical studies using antibiotic-impregnated grafts gave promising results in humans but still need to be confirmed by comparative trials.

6.1.6. Tissue Fillers

59In 1992, study of removed silicone devices, such as mammary implants or tissue expanders led to the identification of bacterial biofilm on the surface of these foreign-bodies. The development of biofilms was associated with the occurrence of capsular contraction, a late complication of such foreign-bodies. A porcine model has been used to study biofilm formation on the surface of breast implants. Implants were inserted with or without a circular disk of minocycline-rifampicin-impregnated polypropylene mesh and left in place for 16 weeks. This preventive approach reduced the incidence of capsular contracture and biofilm formation.

6.1.7. Contact Lenses

60Identification of contact lens as a suitable surface for bacterial adhesion and biofilm formation was made at the end of 80s. Biofilm colonization has also been demonstrated to be associated with the occurrence of corneal ulceration. Several animal models have been developed to study contact lenses tolerance or the influence of bacterial inoculation on the incidence of keratitis such as rabbit model or guinea pig model. While these models have never been used to specifically address questions regarding bacterial biofilms, a specific mouse model has been developed in 2010 in order to study fungal biofilms on contact lenses and its link to keratitis.

6.1.8. Dental Implants

61Confocal laser scanning microscopic studies of oral implants confirmed that biofilm was present with a structure close to what is seen in dental plaque. It has also been shown that the development of these dental implant-related biofilms could play a role in periimplant infections (also called periimplantitis) and progressive bone loss around the implant. The first animal model of dental implant-associated infections was developed in 1992 involving the replacement of mandibular right premolars by complete titanium implants. In this model, mucosal lesions around implant-associated plaque or teeth-associated plaque were comparable but bacterial biofilm per se has not been studied. However, a rat model has been developed to specifically study the effect of Aggregatibacter actinomycetemcomitans biofilm.

62Aside from these animal models, different groups developed human models. All these human models rely on the positioning of a fixation system applied on the mandibular region, inside the mouth of healthy volunteers on which disks made of various surfaces can be placed. For instance, this approach has been used to study the impact of surface roughness on plaque colonization of titanium device. Another group used this approach to demonstrate that bacterial adhesion on implant surfaces was significantly lower with zirconium oxide surface as compared with pure titanium.

6.2.1. Tissue Cage

63These models were developed in the early 80’s to mimic a foreign-body-related infection. These cages consist in rigid tubes with perforations and sealed at each end. These devices can be implanted in mice, rats, hamsters, guinea pigs and ponies. Bacterial contamination can be made before or after tissue cage insertion by a percutaneous injection inside the tissue cage. This model has been used to study different aspects ranging from the influence of host immune response to the effectiveness of different treatments. For instance, the efficacy of adjunction of rifampicin in treatment regimen was suggested in tissue cage models before being confirmed in clinical studies. Fosfomycin and daptomycin are currently being investigated and could be promising candidates against foreign-body-related infections. For an extensive review of these models, see.

6.2.2. Vascular Catheters

64This model has mostly been developed using mice and involves the insertion of a 1-cm segment of vascular catheter under the skin, in a subcutaneous space. The biomaterial can be contaminated by bacteria before or after the surgical procedure and various biomaterials have been used including Teflon®, polyurethane, silastic, latex, dacron, Gortex®. This model was, for example, used to study the importance of staphylococcal accessory regulator (sarA) and ica for S. aureus in vivo biofilm formation. Another group recently demonstrated that there was a reduction in cytokine production during biofilm formation and limited macrophage invasion into S. aureus biofilms in vivo. This model can be used to assess therapeutic options in order to mimic ALT with the injection of antibiotic inside the lumen of subcutaneous catheters. Preventive approaches can also be assessed like the use of cerium nitrate, chitosan and hamamelitannin to prevent the formation of biofilm of S. epidermidis, S. aureus, Acinetobacter baumannii or C. albicans. Many authors use bioluminescent variants of bacteria to follow colonization non-invasively. Using a rabbit model of subcutaneous catheters, minocycline and rifampin coating prevented the colonization by S. aureus, which later was demonstrated to be more efficient than chlorhexidine+silver sulfadiazine coated vascular catheters in a human clinical trial. Other vascular catheter coatings have been studied such as triclosan and dispersin B (an antibiofilm enzyme) to prevent S. aureus colonization.

6.2.3. Other Subcutaneous Models

65Bone cement. A study comparing two commercial acrylic bone cements shaped like a disk demonstrated that association of gentamicin-loaded cement and pulsed ultrasound reduced by 50% the number of viable bacteria recovered from the surface of the implant after sacrifice.

66Pacing device. A rabbit model has been developed to study biofilm formation on the surface of a pacing device, which demonstrated that the use of a mesh envelope incorporating minocycline and rifampicin around the device prevented biofilm formation of S. epidermidis, S. capitis, E. coli and A. baumannii.

67Cardiac valves. To study cardiac valve-related infections, in vivo models were developed in guinea pigs, mice and rabbits. This type of studies focused on the use of silver-coated polyester fabric or minocycline/rifampin coated sewing cuffs to prevent bacterial colonization and infection.

68Vascular grafts. Different models were developed in hamster, mice and rats. These models have been used to study preventive approaches such as antibiotic bonded grafts or vancomycin delivered from glycerylmonostearate (GMS) implants. Different curative approaches have been studied using these models including intraabscess urokinase associated with systemic gentamicin or quorum-sensing inhibitor FS3-coated vascular graft associated with daptomycin.

69Polyethylene disks. Subcutaneous implantation of polyethylene disks in mice or rabbits showed promising effects of ultrasound combined with systemic gentamicin against E. coli.

70Beads. Polymethylmethacrylate beads loaded with or without the quorum-sensing inhibitor RIP associated with or without vancomycin were inserted in subcutaneous space of rats. This approach efficiently prevented S. aureus biofilm formation.

71Surgical meshes. This model involves the insertion of resorbable or non resorbable surgical meshes colonized by S. aureus biofilm inside subcutaneous pockets. While biofilm persisted around non-degradable meshes up to 28 days, bacteria disappeared from surrounding tissues in case of degradable mesh.

7.1. Pitfalls of in vivo Biofilm-Related Infection Models

72As discussed in this review, use of numerous in vitro and in vivo models in the last twenty years has provided massive information on most human biofilm-related infections, even though models dedicated to some biofilm-related infections are missing (see Table 4). Numerous in vivo models have been developed for each infectious disease to address specific questions regarding initial adhesion, assessment of different surfaces, preventive or curative approaches, as illustrated by the large number of models used to study CVC-related infections. Therefore, there is no “gold-standard” as each model may provide an answer to a specific question, depending on host immune system, size or surface of the device and environment. These multiple models provide researchers with a myriad of options in order to choose the more appropriate model that will answer the biological question raised. However, a concerted effort is needed to standardize studies using identical models (in term of animal lineages, route and dose of inoculation, etc.) so that scientists using the same model can compare their results. For instance, among studies dealing with ALT for CVC-related infections, several drugs were studied at different concentrations or dwelling times, therefore, impeding any comparisons between results. In other fields, scientists have proposed guidelines to standardize assays and their interpretation in order to homogenize their results (see for instance). Such an effort should be made in in vivo modeling of biofilm-related infections.

73Furthermore, many concerns have been raised regarding the scarce translation from in vitro and in vivo models to clinical studies. This drawback is not limited to the field of microbiology but probably reflects limitations of in vivo studies. First, obviously, differences exist between humans and animals used for in vivo studies, especially response towards microorganisms or their components. A striking example of the latter is the difference between human and murine sensitivity to LPS that may distort conclusions of studies relying only on this model. Secondly, the choice of animal for in vivo studies is frequently based on experimental convenience and rarely include environmental factors that have been shown to have important influence on the outcome of an infection. The same can be argued for the choice of bacterial strains that may not be representative of the natural setting. One well-known example is the use of non-mucoid PAO1 P. aeruginosa laboratory strain that causes acute types of infection, which are not representative of the clinical symptoms in CF chronic infection. Lastly, as for other in vivo studies, rigorous statistical analysis and experimental set-up are mandatory in order to avoid any false positive interpretation. One can foresee that recent publication of new guidelines for reporting animal research will improve quality of experimental in vivo models.

7.2.1. Synergy between Biofilm Tolerance and Resistance Genes and Their Impact on Nosocomial Infections

74One major challenge of biofilm research is to understand and tackle the increased tolerance of biofilms towards antimicrobial agents including antibiotics. This ability to endure high concentration of antibiotics complicates treatment of biofilm-related infections and is a threat that is enhanced by microorganisms carrying resistance genes such as extended spectrum β-lactamase (ESBL) or methicillin-resistance. Increased frequency of horizontal transfers such as conjugation, transformation or transduction has been demonstrated in vitro within biofilms. Hence, biofilms may also be expected to facilitate the transfer of resistance genes as demonstrated in an in vitro study with an increased rate of transfer of a plasmid encoding CTX-M-15 (an ESBL) in a K. pneumoniae biofilm as compared to planktonic conditions. Interestingly, many transmissible DNA elements encode biofilm promoting factors including various adhesins such as conjugative pili, fimbriae or autotransporter adhesins and persistence genes such as toxin/anti-toxin modules. This, therefore somehow promotes their own transfer by means of their capacity to increase biofilm formation or antibiotic tolerance. Additionally, these phenomenon may be favored by architecture of biofilms in which antibiotics reach certain areas of biofilms only at sub-inhibitory concentrations that are known to increase (i) the likelihood of selecting resistant mutants; (ii) rate of mutations; (iii) biofilm formation and (iv) gene transfer.

75The possible interplay between biofilm tolerance, gene transfer and spread of resistance can be of key-importance in nosocomial settings but remains to be demonstrated in clinical settings or even in a relevant in vivo model of biofilm-related infections. Therefore, establishing in vivo models allowing the study of mechanisms developed by biofilm bacteria to survive antibiotics is a major challenge that should be met in the coming years.

7.2.2. A Switch towards Models to Study Biofilm Polymicrobial Infections?

76While environmental biofilms are known to be composed of multiple species, the concept and demonstration that human infections can arise in the context of polymicrobial biofilms has been overlooked until recently. Koch’s postulates associating one microorganism with one disease as well as the extensive use of culture-dependent isolation techniques have for long time masked the possibility that the nature of the flora among which the pathogenic bacteria are embedded can strongly influence its behavior and the infection outcome. Today, due to the advent of culture-independent methodologies, many tissue infectious diseases are likely associated with the presence of multiple microorganisms like otitis media, oral cavity diseases, vaginosis, wound infections and CF lung infections. The formal demonstration of the existence of polymicrobial biofilms and their link to infection is still a matter of debate (see the reviews). Nevertheless, several studies allowed direct visualization of polymicrobial biofilms in patients. For instance, electron microscopy studies of biofilm in chronic wounds demonstrated the presence of biofilm composed of bacteria of various morphotypes (rods and cocci). This diversity was confirmed using molecular biology tools. Specific FISH probes were also used to show that some biofilms in chronic otitis media are composed of H. influenzae and S. pneumoniae. Interestingly, analyses of the flora comprising biofilms responsible for catheter associated infections like CAUTI or catheter-related bloodstream infections (CRBSI) also demonstrated the presence of multiple species. It is therefore suspected that a large part of biofilm-related infections might be indeed linked to the presence of polymicrobial biofilms. Until now, several well-suited in vitro models to characterize interactions between species have been developed especially using microorganisms colonizing the oral cavity, the intestine or wound infections (see, for example). Surrogate non-mammalian animal models are also used to study such polymicrobial interactions within biofilms. For instance, the behavior of P. aeruginosa in presence of other bacteria such as S. aureus and that of A. actinomycetemcomitans in presence of S. gordonii was analyzed using D. melanogaster. While relatively few, several studies of polymicrobial infections using in vivo mammalian models have been conducted recently using otitis media, wound, UTI or CF lung models. Although these studies were performed with different models and microorganisms, they showed that the colonization, infection and host response was totally different depending on single or multiple species infections with notably an increased ability to colonize or cause host damages/inflammation in co-infections. These promising results urge for rapid implementation of studies aiming not only to analyze the possible polymicrobial status of still unstudied biofilm-related infections but also focusing on development of specific polymicrobial biofilm models. These future studies will certainly help to elucidate molecular mechanisms of bacterial interactions that would ultimately lead to the potential identification of molecules or vaccines that can target polymicrobial biofilms.

7.2.3. What Can We Expect from Systems Biology, Computational Biology, Ecology or Experimental Evolution?

77Until now, studies of polymicrobial infections using in vivo mammalian models remain scarce probably due to the increased complexity to develop such experimental models and the difficulty to interpret results coming both from interactions between the microorganisms and the hosts, and between microorganisms themselves. Significant progress in this area could be made by integrating new concepts and approaches to understand better the ecology of infectious diseases such as the one causing gut disorders or leading to lung destruction in CF patients.

78In these complex structured ecological systems diseases are predicted to originate from the modification of the dynamic of interactions between pathogens, commensal and the hosts systems, and to be strongly dependent on the composition of the environment. Computational modeling is a common tool used to understand many biological processes, such as epidemiological dynamics and emergence of antibiotic resistance. Such approach has allowed genome-scale metabolic reconstruction of several pathogens including P. aeruginosa, S. aureus, Burkholderia spp. or Salmonella spp. and have been used to predict the behavior of bacteria in complex in vivo modeled environments including biofilms leading to the identification of potential target genes or lethal specific environment conditions awaiting in vivo validation. With metabolic multi-cells modeling, taking into account interactions between microorganisms and eukaryotic cells, should come a better understanding of potential complex interactions. Efforts have been made to model various aspects or properties of biofilms such as, for instance, heterogeneity within biofilms or more recently to integrate biofilm formation and development with host dynamics (for example,). Indeed, aspects of evolution are also important to integrate to biofilm-related infections because outcome of the chronicity of such diseases may result from long lasting interactions and co-evolution between microorganisms and hosts. Experimental evolution is a powerful tool that in combination with high throughput sequencing technology can help decipher the genetic and molecular basis of evolutionary change. Such an approach, that has notably been used in medicine to develop attenuated live vaccines, has also been successfully used to understand micro-evolution and patho-adaptative mutations of P. aeruginosa and B. cenopacia, both in patients and in in vitro or in vivo murine models, during modeled or real chronic airway infections. These long-term studies identified bacterial functions that can favor persistent life style of these pathogens and that can have important clinical implications for management of the disease progression. These results may also apply to various biofilm-related chronic infections. Thus, specific in vivo models of tissue or devices-associated infections could shed light over the various selective pressures acting on biofilm physiology and promoting bacterial diversity or the response of biofilm bacteria to different antibiotic treatments.

79The world of infectious diseases is today taking a major turn towards the identification and integration of the multiple parameters influencing diseases' outcome. A better spatial and temporal understanding of dynamic interactions between the microorganisms, the hosts and their environment will open a myriad of possibilities for clinicians to perform in the future an adaptive management of human infections not solely centered on antibiotics but playing with stability of communities or resource competition. Biofilm research has its place to take in this new exciting challenge.

References 462

1.
Henrici A.T. Studies of freshwater bacteria: I. A direct microscopic technique. J. Bacteriol. 1933;25:277-287.
Not in our library10.1128/jb.25.3.277-287.1933
2.
Costerton J.W., Geesey G.G., Cheng K.J. How bacteria stick. Sci. Am. 1978;238:86-95.
Not in our library10.1038/scientificamerican0178-86
3.
Geesey G.G., Richardson W.T., Yeomans H.G., Irvin R.T., Costerton J.W. Microscopic examination of natural sessile bacterial populations from an alpine stream. Can. J. Microbiol. 1977;23:1733-1736.
Not in our library10.1139/m77-249
4.
Al-Azemi A., Fielder M.D., Abuknesha R.A., Price R.G. Effects of chelating agent and environmental stresses on microbial biofilms: relevance to clinical microbiology. J. Appl. Microbiol. 2011;110:1307-1313.
Not in our library10.1111/j.1365-2672.2011.04983.x
5.
Hoiby N., Bjarnsholt T., Givskov M., Molin S., Ciofu O. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents. 2010;35:322-332.
Not in our library10.1016/j.ijantimicag.2009.12.011
6.
Iibuchi R., Hara-Kudo Y., Hasegawa A., Kumagai S. Survival of Salmonella on a polypropylene surface under dry conditions in relation to biofilm-formation capability. J. Food Prot. 2010;73:1506-1510.
Not in our library10.4315/0362-028x-73.8.1506
7.
Fungal Biofilms and Drug Resistance · 2004
No notice
8.
McKew B.A., Taylor J.D., McGenity T.J., Underwood G.J. Resistance and resilience of benthic biofilm communities from a temperate saltmarsh to desiccation and rewetting. Isme J. 2011;5:30-41.
Not in our library10.1038/ismej.2010.91
9.
Costerton J.W. The etiology and persistence of cryptic bacterial infections: a hypothesis. Rev. Infect. Dis. 1984;6(Suppl 3):S608-S616.
Not in our library10.1093/clinids/6.supplement_3.s608
10.
Costerton J.W., Irvin R.T., Cheng K.J. The bacterial glycocalyx in nature and disease. Annu. Rev. Microbiol. 1981;35:299-324.
Not in our library10.1146/annurev.mi.35.100181.001503
11.
Costerton J.W., Irvin R.T., Cheng K.J. The role of bacterial surface structures in pathogenesis. Crit. Rev. Microbiol. 1981;8:303-338.
Not in our library10.3109/10408418109085082
12.
Hoiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol. Microbiol. Scand. Suppl. 1977;1-96.
Not in our library
13.
Hoiby N., Doring G., Schiotz P.O. The role of immune complexes in the pathogenesis of bacterial infections. Annu. Rev. Microbiol. 1986;40:29-53.
Not in our library10.1146/annurev.mi.40.100186.000333
14.
Lam J., Chan R., Lam K., Costerton J.W. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect. Immun. 1980;28:546-556.
Not in our library10.1128/iai.28.2.546-556.1980
15.
Potera C. Forging a link between biofilms and disease. Science. 1999;283:1837-1839.
Not in our library10.1126/science.283.5409.1837
16.
NIH RESEARCH ON MICROBIAL BIOFILMS.
Not in our library
17.
Lebeaux D., Ghigo J.M. Management of biofilm-associated infections: what can we expect from recent research on biofilm lifestyles? Med. Sci. (Paris). 2012;28:727-739.
Not in our library10.1051/medsci/2012288015
18.
Cremieux A.C., Carbon C. Experimental models of bone and prosthetic joint infections. Clin. Infect. Dis. 1997;25:1295-1302.
Not in our library10.1086/516135
19.
Morton D.B. Ethical considerations in the use of animal models in infection. Clin. Microbiol. Infect. 1998;4:613-614.
Not in our library
20.
Russell W.M.S., Burch R.L. The Principles of Humane Experimental Technique. 1959.
Not in our library
21.
McBain A.J. Chapter 4: In vitro biofilm models: an overview. Adv. Appl. Microbiol. 2009;69:99-132.
Not in our library10.1016/s0065-2164(09)69004-3
22.
Coenye T., Nelis H.J. In vitro and in vivo model systems to study microbial biofilm formation. J. Microbiol. Methods. 2010;83:89-105.
Not in our library10.1016/j.mimet.2010.08.018
23.
Christensen G.D., Simpson W.A., Younger J.J., Baddour L.M., Barrett F.F., Melton D.M., Beachey E.H. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J. Clin. Microbiol. 1985;22:996-1006.
Not in our library10.1128/jcm.22.6.996-1006.1985
24.
Stepanovic S., Vukovic D., Hola V., Di Bonaventura G., Djukic S., Cirkovic I., Ruzicka F. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS. 2007;115:891-899.
Not in our library10.1111/j.1600-0463.2007.apm_630.x
25.
Rudney J.D., Chen R., Lenton P., Li J., Li Y., Jones R.S., Reilly C., Fok A.S., Aparicio C. A reproducible oral microcosm biofilm model for testing dental materials. J. Appl. Microbiol. 2012;113:1540-1553.
Not in our library10.1111/j.1365-2672.2012.05439.x
26.
Berry R.E., Klumpp D.J., Schaeffer A.J. Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli. Infect. Immun. 2009;77:2762-2772.
Not in our library10.1128/iai.00323-09
27.
Harriott M.M., Lilly E.A., Rodriguez T.E., Fidel P.L., Noverr M.C. Candida albicans forms biofilms on the vaginal mucosa. Microbiology. 2010;156:3635-3644.
Not in our library10.1099/mic.0.039354-0
28.
Lenton P., Rudney J., Chen R., Fok A., Aparicio C., Jones R.S. Imaging in vivo secondary caries and ex vivo dental biofilms using cross-polarization optical coherence tomography. Dental materials. 2012;28:792-800.
Not in our library10.1016/j.dental.2012.04.004
29.
Uropathogenic Escherichia coli P and Type 1 Fimbriae Act in Synergy in a Living Host to Facilitate Renal Colonization Leading to Nephron Obstruction · 2011
No notice
30.
Simmons W.L., Dybvig K. Mycoplasma biofilms ex vivo and in vivo. FEMS Microbiol. Lett. 2009;295:77-81.
Not in our library10.1111/j.1574-6968.2009.01592.x
31.
Wolcott R.D., Rumbaugh K.P., James G., Schultz G., Phillips P., Yang Q., Watters C., Stewart P.S., Dowd S.E. Biofilm maturity studies indicate sharp debridement opens a time- dependent therapeutic window. J. Wound Care. 2010;19:320-328.
Not in our library10.12968/jowc.2010.19.8.77709
32.
Boman H.G. Innate immunity and the normal microflora. Immunol. Rev. 2000;173:5-16.
Not in our library10.1034/j.1600-065x.2000.917301.x
33.
Lemaitre B., Ausubel F. Animal models for host-pathogen interactions. Curr. Opin. Microbiol. 2008;11:249-250.
Not in our library10.1016/j.mib.2008.05.002
34.
Zhang Y., Hu Y., Yang B., Ma F., Lu P., Li L., Wan C., Rayner S., Chen S. Duckweed (Lemna minor) as a model plant system for the study of human microbial pathogenesis. PLoS One. 2010;5:e13527.
Not in our library10.1371/journal.pone.0013527
35.
Diard M., Baeriswyl S., Clermont O., Gouriou S., Picard B., Taddei F., Denamur E., Matic I. Caenorhabditis elegans as a simple model to study phenotypic and genetic virulence determinants of extraintestinal pathogenic Escherichia coli. Microbes and infection. 2007;9:214-223.
Not in our library10.1016/j.micinf.2006.11.009
36.
De Bentzmann S., Giraud C., Bernard C.S., Calderon V., Ewald F., Plesiat P., Nguyen C., Grunwald D., Attree I., Jeannot K., et al. Unique Biofilm signature, drug susceptibility and decreased virulence in Drosophila through the Pseudomonas aeruginosa two-component system PprAB. PLoS Pathog. 2012;8:e1003052.
Not in our library10.1371/journal.ppat.1003052
37.
Mulcahy H., Sibley C.D., Surette M.G., Lewenza S. Drosophila melanogaster as an animal model for the study of Pseudomonas aeruginosa biofilm infections in vivo. PLoS Pathog. 2011;7:e1002299.
Not in our library10.1371/journal.ppat.1002299
38.
Purdy A.E., Watnick P.I. Spatially selective colonization of the arthropod intestine through activation of Vibriocholerae biofilm formation. Proc. Natl. Acad. Sci. USA. 2011;108:19737-19742.
Not in our library10.1073/pnas.1111530108
39.
Neely M.N., Pfeifer J.D., Caparon M. Streptococcus-zebrafish model of bacterial pathogenesis. Infect. Immun. 2002;70:3904-3914.
Not in our library10.1128/iai.70.7.3904-3914.2002
40.
Rawls J.F., Mahowald M.A., Goodman A.L., Trent C.M., Gordon J.I. In vivo imaging and genetic analysis link bacterial motility and symbiosis in the zebrafish gut. Proc. Natl. Acad. Sci. USA. 2007;104:7622-7627.
Not in our library10.1073/pnas.0702386104
41.
Rendueles O., Ferrieres L., Fretaud M., Begaud E., Herbomel P., Levraud J.P., Ghigo J.M. A new zebrafish model of Oro-intestinal pathogen colonization reveals a key role for adhesion in protection by probiotic bacteria. PLoS Pathog. 2012;8:e1002815.
Not in our library10.1371/journal.ppat.1002815
42.
Letamendia A., Quevedo C., Ibarbia I., Virto J.M., Holgado O., Diez M., Izpisua Belmonte J.C., Callol-Massot C. Development and validation of an automated high-throughput system for zebrafish in vivo screenings. PLoS One. 2012;7:e36690.
Not in our library10.1371/journal.pone.0036690
43.
Ahlund M.K., Ryden P., Sjostedt A., Stoven S. Directed screen of Francisellanovicida virulence determinants using Drosophila melanogaster. Infect. Immun. 2010;78:3118-3128.
Not in our library10.1128/iai.00146-10
44.
Kurz C.L., Chauvet S., Andres E., Aurouze M., Vallet I., Michel G.P., Uh M., Celli J., Filloux A., De Bentzmann S., et al. Virulence factors of the human opportunistic pathogen Serratia marcescens identified by in vivo screening. EMBO J. 2003;22:1451-1460.
Not in our library10.1093/emboj/cdg159
45.
Zebrafish embryo screen for mycobacterial genes involved in the initiation of granuloma formation reveals a newly identified ESX-1 component · 2011
Not checked
46.
Joshua G.W., Karlyshev A.V., Smith M.P., Isherwood K.E., Titball R.W., Wren B.W. A Caenorhabditis elegans model of Yersinia infection: biofilm formation on a biotic surface. Microbiology. 2003;149:3221-3229.
Not in our library10.1099/mic.0.26475-0
47.
Silver A.C., Rabinowitz N.M., Küffer S., Graf J. Identification of Aeromonas veronii genes required for colonization of the medicinal leech, Hirudo verbana. J. Bacteriol. 2007;189:6763-6772.
Not in our library10.1128/jb.00685-07
48.
Squiban B., Kurz C.L. C. elegans: an all in one model for antimicrobial drug discovery. Curr. Drug Targets. 2011;12:967-977.
Not in our library10.2174/138945011795677854
49.
Pradel E., Ewbank J.J. Genetic models in pathogenesis. Ann. Rev. Genet. 2004;38:347-363.
Not in our library10.1146/annurev.genet.38.072902.092528
50.
Cohen T.S., Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat. Med. 2012;18:509-519.
Not in our library10.1038/nm.2715
51.
Hoiby N., Ciofu O., Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol. 2010;5:1663-1674.
Not in our library10.2217/fmb.10.125
52.
Lyczak J.B., Cannon C.L., Pier G.B. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 2002;15:194-222.
Not in our library10.1128/cmr.15.2.194-222.2002
53.
Singh P.K., Schaefer A.L., Parsek M.R., Moninger T.O., Welsh M.J., Greenberg E.P. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000;407:762-764.
Not in our library10.1038/35037627
54.
Cash H.A., Woods D.E., McCullough B., Johanson W.G., Bass J.A. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am. Rev. Respir. Dis. 1979;119:453-459.
Not in our library10.1164/arrd.1979.119.3.453
55.
Bernier S.P., Silo-Suh L., Woods D.E., Ohman D.E., Sokol P.A. Comparative analysis of plant and animal models for characterization of Burkholderia cepacia virulence. Infect. Immun. 2003;71:5306-5313.
Not in our library10.1128/iai.71.9.5306-5313.2003
56.
Cheung A.T., Moss R.B., Leong A.B., Novick W.J. Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys: I. Effects of pentoxifylline on neutrophil influx. J. Med. Primatol. 1992;21:357-362.
Not in our library
57.
Starke J.R., Edwards M.S., Langston C., Baker C.J. A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia. Pediatr. Res. 1987;22:698-702.
Not in our library10.1203/00006450-198712000-00017
58.
Thomassen M.J., Klinger J.D., Winnie G.B., Wood R.E., Burtner C., Tomashefski J.F., Horowitz J.G., Tandler B. Pulmonary cellular response to chronic irritation and chronic Pseudomonas aeruginosa pneumonia in cats. Infect. Immun. 1984;45:741-747.
Not in our library10.1128/iai.45.3.741-747.1984
59.
Winnie G.B., Klinger J.D., Sherman J.M., Thomassen M.J. Induction of phagocytic inhibitory activity in cats with chronic Pseudomonas aeruginosa pulmonary infection. Infect. Immun. 1982;38:1088-1093.
Not in our library10.1128/iai.38.3.1088-1093.1982
60.
van Heeckeren A.M., Schluchter M.D. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab. Anim. 2002;36:291-312.
Not in our library10.1258/002367702320162405
61.
Alhariri M., Omri A. Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa Infection. Antimicrob. Agents Chemother. 2013;57:569-578.
Not in our library10.1128/aac.01634-12
62.
Pedersen S.S., Shand G.H., Hansen B.L., Hansen G.N. Induction of experimental chronic Pseudomonas aeruginosa lung infection with P. aeruginosa entrapped in alginate microspheres. APMIS. 1990;98:203-211.
Not in our library10.1111/j.1699-0463.1990.tb01023.x
63.
Yang L., Hengzhuang W., Wu H., Damkiaer S., Jochumsen N., Song Z., Givskov M., Hoiby N., Molin S. Polysaccharides serve as scaffold of biofilms formed by mucoid Pseudomonas aeruginosa. FEMS Immunol. Med. Microbiol. 2012;65:366-376.
Not in our library10.1111/j.1574-695x.2012.00936.x
64.
Hengzhuang W., Wu H., Ciofu O., Song Z., Hoiby N. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob. Agents Chemother. 2011;56:2683-2690.
Not in our library10.1128/aac.06486-11
65.
Sawai T., Tomono K., Yanagihara K., Yamamoto Y., Kaku M., Hirakata Y., Koga H., Tashiro T., Kohno S. Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of Staphylococcus aureus enmeshed in agar beads. Infect. Immun. 1997;65:466-471.
Not in our library10.1128/iai.65.2.466-471.1997
66.
Kihara R., Yanagihara K., Morinaga Y., Araki N., Nakamura S., Seki M., Izumikawa K., Kakeya H., Yamamoto Y., Tsukamoto K., et al. Potency of SMP-601, a novel carbapenem, in hematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2008;52:2163-2168.
Not in our library10.1128/aac.01532-07
67.
Yanagihara K., Kihara R., Araki N., Morinaga Y., Seki M., Izumikawa K., Kakeya H., Yamamoto Y., Yamada Y., Kohno S., et al. Efficacy of linezolid against Panton-Valentine leukocidin (PVL)-positive meticillin-resistant Staphylococcus aureus (MRSA) in a mouse model of haematogenous pulmonary infection. Int. J. Antimicrob. Agents. 2009;34:477-481.
Not in our library10.1016/j.ijantimicag.2009.06.024
68.
Clarke L.L., Grubb B.R., Gabriel S.E., Smithies O., Koller B.H., Boucher R.C. Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis. Science. 1992;257:1125-1128.
Not in our library10.1126/science.257.5073.1125
69.
Bragonzi A. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int. J. Med. Microbiol. 2010;300:584-593.
Not in our library10.1016/j.ijmm.2010.08.012
70.
Hoffmann N., Lee B., Hentzer M., Rasmussen T.B., Song Z., Johansen H.K., Givskov M., Hoiby N. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob. Agents Chemother. 2007;51:3677-3687.
Not in our library10.1128/aac.01011-06
71.
Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., Coquillette S., Fieberg A.Y., Accurso F.J., Campbell P.W. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA J. Am. Med. Assoc. 2003;290:1749-1756.
Not in our library10.1001/jama.290.13.1749
72.
Bragonzi A., Farulla I., Paroni M., Twomey K.B., Pirone L., Lore N.I., Bianconi I., Dalmastri C., Ryan R.P., Bevivino A. Modelling co-infection of the cystic fibrosis lung by Pseudomonas aeruginosa and Burkholderia cenocepacia reveals influences on biofilm formation and host response. PLoS One. 2012;7:e52330.
Not in our library10.1371/journal.pone.0052330
73.
Stoltz D.A., Meyerholz D.K., Pezzulo A.A., Ramachandran S., Rogan M.P., Davis G.J., Hanfland R.A., Wohlford-Lenane C., Dohrn C.L., Bartlett J.A., et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci. Transl. Med. 2010;2:29ra31.
Not in our library10.1126/scitranslmed.3000928
74.
Keiser N.W., Engelhardt J.F. New animal models of cystic fibrosis: what are they teaching us? Curr. Opin. Pulm. Med. 2011;17:478-483.
Not in our library10.1097/mcp.0b013e32834b14c9
75.
Sethi S., Wrona C., Eschberger K., Lobbins P., Cai X., Murphy T.F. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008;177:491-497.
Not in our library10.1164/rccm.200708-1234oc
76.
Pang B., Hong W., West-Barnette S.L., Kock N.D., Swords W.E. Diminished ICAM-1 expression and impaired pulmonary clearance of nontypeable Haemophilus influenzae in a mouse model of chronic obstructive pulmonary disease/emphysema. Infect. Immun. 2008;76:4959-4967.
Not in our library10.1128/iai.00664-08
77.
Homma H., Yamanaka A., Tanimoto S., Tamura M., Chijimatsu Y., Kira S., Izumi T. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest. 1983;83:63-69.
Not in our library10.1378/chest.83.1.63
78.
Kobayashi H. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections. Treat. Respir. Med. 2005;4:241-253.
Not in our library10.2165/00151829-200504040-00003
79.
Schultz M.J. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J. Antimicrob. Chemother. 2004;54:21-28.
Not in our library10.1093/jac/dkh309
80.
Yanagihara K., Tomono K., Sawai T., Hirakata Y., Kadota J., Koga H., Tashiro T., Kohno S. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 1997;155:337-342.
Not in our library10.1164/ajrccm.155.1.9001333
81.
Nagata T., Mukae H., Kadota J., Hayashi T., Fujii T., Kuroki M., Shirai R., Yanagihara K., Tomono K., Koji T., et al. Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. Antimicrob. Agents Chemother. 2004;48:2251-2259.
Not in our library10.1128/aac.48.6.2251-2259.2004
82.
Yanagihara K., Tomono K., Sawai T., Kuroki M., Kaneko Y., Ohno H., Higashiyama Y., Miyazaki Y., Hirakata Y., Maesaki S., et al. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. J. Antimicrob. Chemother. 2000;46:69-72.
Not in our library10.1093/jac/46.1.69
83.
Hannan T.J., Totsika M., Mansfield K.J., Moore K.H., Schembri M.A., Hultgren S.J. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol. Rev. 2012;36:616-648.
Not in our library10.1111/j.1574-6976.2012.00339.x
84.
Conway P.H., Cnaan A., Zaoutis T., Henry B.V., Grundmeier R.W., Keren R. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA J. Am. Med. Assoc. 2007;298:179-186.
Not in our library10.1001/jama.298.2.179
85.
Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am. J. Med. 2002;113(Suppl 1A):14S-19S.
Not in our library10.1016/s0002-9343(02)01055-0
86.
Ozok H.U., Ekim O., Saltas H., Arikok A.T., Babacan O., Sagnak L., Topaloglu H., Ersoy H. The preventive role of transurethral antibiotic delivery in a rat model. Drug Des. Dev. Ther. 2012;6:187-194.
Not in our library10.2147/dddt.s32733
87.
Hung C.S., Dodson K.W., Hultgren S.J. A murine model of urinary tract infection. Nat. Protoc. 2009;4:1230-1243.
Not in our library10.1038/nprot.2009.116
88.
Detection of Intracellular Bacterial Communities in Human Urinary Tract Infection · 2007
No notice
89.
Anderson G.G., Palermo J.J., Schilling J.D., Roth R., Heuser J., Hultgren S.J. Intracellular bacterial biofilm-like pods in urinary tract infections. Science. 2003;301:105-107.
Not in our library10.1126/science.1084550
90.
Blango M.G., Mulvey M.A. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob. Agents Chemother. 2010;54:1855-1863.
Not in our library10.1128/aac.00014-10
91.
Justice S.S., Hung C., Theriot J.A., Fletcher D.A., Anderson G.G., Footer M.J., Hultgren S.J. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc. Natl. Acad. Sci. USA. 2004;101:1333-1338.
Not in our library10.1073/pnas.0308125100
92.
Cusumano C.K., Pinkner J.S., Han Z., Greene S.E., Ford B.A., Crowley J.R., Henderson J.P., Janetka J.W., Hultgren S.J. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci. Transl. Med. 2011;3:109ra115.
Not in our library10.1126/scitranslmed.3003021
93.
Hadjifrangiskou M., Kostakioti M., Chen S.L., Henderson J.P., Greene S.E., Hultgren S.J. A central metabolic circuit controlled by QseC in pathogenic Escherichia coli. Mol. Microbiol. 2011;80:1516-1529.
Not in our library10.1111/j.1365-2958.2011.07660.x
94.
Fitness of Escherichia coli during Urinary Tract Infection Requires Gluconeogenesis and the TCA Cycle · 2009
No notice
95.
Hultgren S.J., Porter T.N., Schaeffer A.J., Duncan J.L. Role of type 1 pili and effects of phase variation on lower urinary tract infections produced by Escherichia coli. Infect. Immun. 1985;50:370-377.
Not in our library10.1128/iai.50.2.370-377.1985
96.
Abraham S.N., Babu J.P., Giampapa C.S., Hasty D.L., Simpson W.A., Beachey E.H. Protection against Escherichia coli-induced urinary tract infections with hybridoma antibodies directed against type 1 fimbriae or complementary D-mannose receptors. Infect. Immun. 1985;48:625-628.
Not in our library10.1128/iai.48.3.625-628.1985
97.
Wright K.J., Seed P.C., Hultgren S.J. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell. Microbiol. 2007;9:2230-2241.
Not in our library10.1111/j.1462-5822.2007.00952.x
98.
Poggio T.V., La Torre J.L., Scodeller E.A. Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic Escherichia coli challenge. Can. J. Microbiol. 2006;52:1093-1102.
Not in our library10.1139/w06-065
99.
Brumbaugh A.R., Mobley H.L. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev. Vaccines. 2012;11:663-676.
Not in our library10.1586/erv.12.36
100.
Sunden F., Hakansson L., Ljunggren E., Wullt B. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J. Urol. 2010;184:179-185.
Not in our library10.1016/j.juro.2010.03.024
101.
Watts R.E., Totsika M., Challinor V.L., Mabbett A.N., Ulett G.C., De Voss J.J., Schembri M.A. Contribution of siderophore systems to growth and urinary tract colonization of asymptomatic bacteriuria Escherichia coli. Infect. Immun. 2012;80:333-344.
Not in our library10.1128/iai.05594-11
102.
Fischer H., Lutay N., Ragnarsdottir B., Yadav M., Jonsson K., Urbano A., Al Hadad A., Ramisch S., Storm P., Dobrindt U., et al. Pathogen specific, IRF3-dependent signaling and innate resistance to human kidney infection. PLoS Pathog. 2010;6:e1001109.
Not in our library10.1371/journal.ppat.1001109
103.
Toll-like receptor 4 promoter polymorphisms: common TLR4 variants may protect against severe urinary tract infection. · 2010
Not checked
104.
Sivick K.E., Mobley H.L. Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect. Immun. 2010;78:568-585.
Not in our library10.1128/iai.01000-09
105.
Hansson S., Hanson E., Hjalmas K., Hultengren M., Jodal U., Olling S., Svanborg-Eden C. Follicular cystitis in girls with untreated asymptomatic or covert bacteriuria. J. Urol. 1990;143:330-332.
Not in our library10.1016/s0022-5347(17)39950-0
106.
Schlager T.A., LeGallo R., Innes D., Hendley J.O., Peters C.A. B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J. Urol. 2011;186:2359-2364.
Not in our library10.1016/j.juro.2011.07.114
107.
Wang C., Mendonsa G.R., Symington J.W., Zhang Q., Cadwell K., Virgin H.W., Mysorekar I.U. Atg16L1 deficiency confers protection from uropathogenic Escherichia coli infection in vivo. Proc. Natl. Acad. Sci. USA. 2012;109:11008-11013.
Not in our library10.1073/pnas.1203952109
108.
Naber K.G., Bergman B., Bishop M.C., Bjerklund-Johansen T.E., Botto H., Lobel B., Jinenez Cruz F., Selvaggi F.P. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur. Urol. 2001;40:576-588.
Not in our library10.1159/000049840
109.
Nickel J.C., Costerton J.W. Bacterial localization in antibiotic-refractory chronic bacterial prostatitis. Prostate. 1993;23:107-114.
Not in our library10.1002/pros.2990230204
110.
Krieger J.N., Lee S.W., Jeon J., Cheah P.Y., Liong M.L., Riley D.E. Epidemiology of prostatitis. Int. J. Antimicrob. Agents. 2008;31(Suppl 1):S85-90.
Not in our library10.1016/j.ijantimicag.2007.08.028
111.
Mazzoli S. Biofilms in chronic bacterial prostatitis (NIH-II) and in prostatic calcifications. FEMS Immunol. Med. Microbiol. 2010;59:337-344.
Not in our library10.1111/j.1574-695x.2010.00659.x
112.
Potts J., Payne R.E. Prostatitis: Infection, neuromuscular disorder, or pain syndrome? Proper patient classification is key. Cleve Clin. J. Med. 2007;74(Suppl 3):S63-S71.
Not in our library10.3949/ccjm.74.suppl_3.s63
113.
Garcia-Castillo M., Morosini M.I., Galvez M., Baquero F., del Campo R., Meseguer M.A. Differences in biofilm development and antibiotic susceptibility among clinical Ureaplasma urealyticum and Ureaplasma parvum isolates. J. Antimicrob. Chemother. 2008;62:1027-1030.
Not in our library10.1093/jac/dkn337
114.
Soto S.M., Smithson A., Martinez J.A., Horcajada J.P., Mensa J., Vila J. Biofilm formation in uropathogenic Escherichia coli strains: relationship with prostatitis, urovirulence factors and antimicrobial resistance. J. Urol. 2007;177:365-368.
Not in our library10.1016/j.juro.2006.08.081
115.
Kim H.W., Ha U.S., Woo J.C., Kim S.J., Yoon B.I., Lee S.J., Cho Y.H. Preventive effect of selenium on chronic bacterial prostatitis. J. Infect. Chemother. 2012;18:30-34.
Not in our library10.1007/s10156-011-0276-4
116.
Nelson L.K., D'Amours G.H., Sproule-Willoughby K.M., Morck D.W., Ceri H. Pseudomonas aeruginosa las and rhl quorum-sensing systems are important for infection and inflammation in a rat prostatitis model. Microbiology. 2009;155:2612-2619.
Not in our library10.1099/mic.0.028464-0
117.
Phan V., Belas R., Gilmore B.F., Ceri H. ZapA, a virulence factor in a rat model of Proteus mirabilis-induced acute and chronic prostatitis. Infect. Immun. 2008;76:4859-4864.
Not in our library10.1128/iai.00122-08
118.
Kim S.H., Ha U.S., Lee H.R., Sohn D.W., Lee S.J., Kim H.W., Han C.H., Lee C.B., Cho Y.H. Do Escherichia coli extract and cranberry exert preventive effects on chronic bacterial prostatitis? Pilot study using an animal model. J. Infect. Chemother. 2011;17:322-326.
Not in our library10.1007/s10156-010-0170-5
119.
Lee Y.S., Han C.H., Kang S.H., Lee S.J., Kim S.W., Shin O.R., Sim Y.C., Cho Y.H. Synergistic effect between catechin and ciprofloxacin on chronic bacterial prostatitis rat model. Int. J. Urol. 2005;12:383-389.
Not in our library10.1111/j.1442-2042.2005.01052.x
120.
Bichler K.H., Eipper E., Naber K., Braun V., Zimmermann R., Lahme S. Urinary infection stones. Int. J. Antimicrob. Agents. 2002;19:488-498.
Not in our library10.1016/s0924-8579(02)00088-2
121.
Hinman F. Directional growth of renal calculi. J. Urol. 1979;121:700-705.
Not in our library10.1016/s0022-5347(17)56962-1
122.
Nemoy N.J., Staney T.A. Surgical, bacteriological, and biochemical management of “infection stones”. JAMA J. Am. Med. Assoc. 1971;215:1470-1476.
Not in our library10.1001/jama.1971.03180220052010
123.
Nickel J.C., Reid G., Bruce A.W., Costerton J.W. Ultrastructural microbiology of infected urinary stone. Urology. 1986;28:512-515.
Not in our library10.1016/0090-4295(86)90155-x
124.
Broomfield R.J., Morgan S.D., Khan A., Stickler D.J. Crystalline bacterial biofilm formation on urinary catheters by urease-producing urinary tract pathogens: a simple method of control. J. Future Med. Microbiol. 2009;58:1367-1375.
Not in our library10.1099/jmm.0.012419-0
125.
Campieri C., Campieri M., Bertuzzi V., Swennen E., Matteuzzi D., Stefoni S., Pirovano F., Centi C., Ulisse S., Famularo G., et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int. 2001;60:1097-1105.
Not in our library10.1046/j.1523-1755.2001.0600031097.x
126.
Kwak C., Kim H.K., Kim E.C., Choi M.S., Kim H.H. Urinary oxalate levels and the enteric bacterium Oxalobacter formigenes in patients with calcium oxalate urolithiasis. Eur. Urol. 2003;44:475-481.
Not in our library10.1016/s0302-2838(03)00318-x
127.
Nickel J.C., Olson M., McLean R.J., Grant S.K., Costerton J.W. An ecological study of infected urinary stone genesis in an animal model. Br. J. Urol. 1987;59:21-30.
Not in our library10.1111/j.1464-410x.1987.tb04573.x
128.
Satoh M., Takeuchi H., Munakata K., Yoshida O. Therapeutic effect of cefluprenam on polymicrobial urinary tract infection associated with Enterococcus faecalis, using the infectious urolithiasis model in rats. Kansenshogaku Zasshi. 1998;72:371-378.
Not in our library10.11150/kansenshogakuzasshi1970.72.371
129.
Vermeulen C.W., Goetz R. Experimental urolithiasis. IX. Influence of infection on stone growth in rats. J. Urol. 1954;72:761-769.
Not in our library10.1016/s0022-5347(17)67665-1
130.
Satoh M., Munakata K., Kitoh K., Takeuchi H., Yoshida O. A newly designed model for infection-induced bladder stone formation in the rat. J. Urol. 1984;132:1247-1249.
Not in our library10.1016/s0022-5347(17)50115-9
131.
Nickel J.C., Costerton J.W., McLean R.J., Olson M. Bacterial biofilms: influence on the pathogenesis, diagnosis and treatment of urinary tract infections. J. Antimicrob. Chemother. 1994;33(Suppl A):31-41.
Not in our library10.1093/jac/33.suppl_a.31
132.
Lee F.D., Kraszewski A., Gordon J., Howie J.G., McSeveney D., Harland W.A. Intestinal spirochaetosis. Gut. 1971;12:126-133.
Not in our library10.1136/gut.12.2.126
133.
Macfarlane S., Dillon J.F. Microbial biofilms in the human gastrointestinal tract. J. Appl. Microbiol. 2007;102:1187-1196.
Not in our library10.1111/j.1365-2672.2007.03287.x
134.
Palestrant D., Holzknecht Z.E., Collins B.H., Parker W., Miller S.E., Bollinger R.R. Microbial biofilms in the gut: visualization by electron microscopy and by acridine orange staining. Ultrastruct. Pathol. 2004;28:23-27.
Not in our library
135.
Swidsinski A., Weber J., Loening-Baucke V., Hale L.P., Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol. 2005;43:3380-3389.
Not in our library10.1128/jcm.43.7.3380-3389.2005
136.
Zoetendal E.G., Akkermans A.D., De Vos W.M. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl. Environ. Microbiol. 1998;64:3854-3859.
Not in our library10.1128/aem.64.10.3854-3859.1998
137.
Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
Not in our library10.1038/nature06005
138.
Bohnhoff M., Miller C.P., Martin W.R. Resistance of the Mouse's Intestinal Tract to Experimental Salmonella Infection. Ii. Factors Responsible for Its Loss Following Streptomycin Treatment. J. Exp. Med. 1964;120:817-828.
Not in our library10.1084/jem.120.5.817
139.
Onderdonk A., Marshall B., Cisneros R., Levy S.B. Competition between congenic Escherichia coli K-12 strains in vivo. Infect. Immun. 1981;32:74-79.
Not in our library10.1128/iai.32.1.74-79.1981
140.
Kaiser P., Diard M., Stecher B., Hardt W.D. The streptomycin mouse model for Salmonella diarrhea: functional analysis of the microbiota, the pathogen's virulence factors, and the host's mucosal immune respons. Immunol. Rev. 2012;245:56-83.
Not in our library10.1111/j.1600-065x.2011.01070.x
141.
Eckmann L. Animal models of inflammatory bowel disease: lessons from enteric infections. Ann. N. Y. Acad. Sci. 2006;1072:28-38.
Not in our library10.1196/annals.1326.008
142.
Nell S., Suerbaum S., Josenhans C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat. Rev. Microbiol. 2010;8:564-577.
Not in our library10.1038/nrmicro2403
143.
Dinbar A., Altmann G., Tulcinsky D.B. The treatment of chronic biliary salmonella carriers. Am. J. Med. 1969;47:236-242.
Not in our library10.1016/0002-9343(69)90149-1
144.
Lai C.W., Chan R.C., Cheng A.F., Sung J.Y., Leung J.W. Common bile duct stones: a cause of chronic salmonellosis. Am. J. Gastroenterol. 1992;87:1198-1199.
Not in our library
145.
Sukupolvi S., Edelstein A., Rhen M., Normark S.J., Pfeifer J.D. Development of a murine model of chronic Salmonella infection. Infect. Immun. 1997;65:838-842.
Not in our library10.1128/iai.65.2.838-842.1997
146.
Monack D.M., Bouley D.M., Falkow S. Salmonella typhimurium persists within macrophages in the mesenteric lymph nodes of chronically infected Nramp1+/+ mice and can be reactivated by IFNgamma neutralization. J. Exp. Med. 2004;199:231-241.
Not in our library10.1084/jem.20031319
147.
Crawford R.W., Reeve K.E., Gunn J.S. Flagellated but not hyperfimbriated Salmonella enterica serovar Typhimurium attaches to and forms biofilms on cholesterol-coated surfaces. J. Bacteriol. 2010;192:2981-2990.
Not in our library10.1128/jb.01620-09
148.
Bjarnsholt T., Kirketerp-Moller K., Jensen P.O., Madsen K.G., Phipps R., Krogfelt K., Hoiby N., Givskov M. Why chronic wounds will not heal: a novel hypothesis. Wound Repair. Regen. 2008;16:2-10.
Not in our library10.1111/j.1524-475x.2007.00283.x
149.
James G.A., Swogger E., Wolcott R., Pulcini E., Secor P., Sestrich J., Costerton J.W., Stewart P.S. Biofilms in chronic wounds. Wound Repair. Regen. 2008;16:37-44.
Not in our library10.1111/j.1524-475x.2007.00321.x
150.
Seth A.K., Geringer M.R., Hong S.J., Leung K.P., Mustoe T.A., Galiano R.D. In vivo modeling of biofilm-infected wounds: a review. J. Surg. Res. 2012;178:330-338.
Not in our library10.1016/j.jss.2012.06.048
151.
Thomson C.H. Biofilms: do they affect wound healing? Int. Wound J. 2011;8:63-67.
Not in our library10.1111/j.1742-481x.2010.00749.x
152.
Dai T., Tegos G.P., Zhiyentayev T., Mylonakis E., Hamblin M.R. Photodynamic therapy for methicillin-resistant Staphylococcus aureus infection in a mouse skin abrasion model. Lasers Surg. Med. 2010;42:38-44.
Not in our library10.1002/lsm.20887
153.
Dai T., Kharkwal G.B., Tanaka M., Huang Y.Y., Bil de Arce V.J., Hamblin M.R. Animal models of external traumatic wound infections. Virulence. 2011;2:296-315.
Not in our library10.4161/viru.2.4.16840
154.
Trøstrup H., Thomsen K., Christophersen L.J., Hougen H.P., Bjarnsholt T., Jensen P.Ø., Kirkby N., Calum H., Høiby N., Moser C. Pseudomonas aeruginosa biofilm aggravates skin inflammatory response in BALB/c mice in a novel chronic wound model. Wound Repair Regen. 2013;21:292-299.
Not in our library10.1111/wrr.12016
155.
Calum H., Moser C., Jensen P.O., Christophersen L., Maling D.S., van Gennip M., Bjarnsholt T., Hougen H.P., Givskov M., Jacobsen G.K., et al. Thermal injury induces impaired function in polymorphonuclear neutrophil granulocytes and reduced control of burn wound infection. Clin. Exp. Immunol. 2009;156:102-110.
Not in our library10.1111/j.1365-2249.2008.03861.x
156.
Akiyama H., Kanzaki H., Tada J., Arata J. Staphylococcus aureus infection on cut wounds in the mouse skin: experimental staphylococcal botryomycosis. J. Dermatol. Sci. 1996;11:234-238.
Not in our library10.1016/0923-1811(95)00448-3
157.
Davis S.C., Ricotti C., Cazzaniga A., Welsh E., Eaglstein W.H., Mertz P.M. Microscopic and physiologic evidence for biofilm-associated wound colonization in vivo. Wound Repair. Regen. 2008;16:23-29.
Not in our library10.1111/j.1524-475x.2007.00303.x
158.
Simonetti O., Cirioni O., Ghiselli R., Goteri G., Scalise A., Orlando F., Silvestri C., Riva A., Saba V., Madanahally K.D., et al. NAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2008;52:2205-2211.
Not in our library10.1128/aac.01340-07
159.
Nakagami G., Sanada H., Sugama J., Morohoshi T., Ikeda T., Ohta Y. Detection of Pseudomonas aeruginosa quorum sensing signals in an infected ischemic wound: an experimental study in rats. Wound Repair. Regen. 2008;16:30-36.
Not in our library10.1111/j.1524-475x.2007.00329.x
160.
Citron D.M., Goldstein E.J., Merriam C.V., Lipsky B.A., Abramson M.A. Bacteriology of moderate-to-severe diabetic foot infections and In vitro activity of antimicrobial agents. J. Clin. Microbiol. 2007;45:2819-2828.
Not in our library10.1128/jcm.00551-07
161.
Mastropaolo M.D., Evans N.P., Byrnes M.K., Stevens A.M., Robertson J.L., Melville S.B. Synergy in polymicrobial infections in a mouse model of type 2 diabetes. Infect. Immun. 2005;73:6055-6063.
Not in our library10.1128/iai.73.9.6055-6063.2005
162.
Donlan R.M., Costerton J.W. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 2002;15:167-193.
Not in our library10.1128/cmr.15.2.167-193.2002
163.
Gotz F. Staphylococcus and biofilms. Mol. Microbiol. 2002;43:1367-1378.
Not in our library10.1046/j.1365-2958.2002.02827.x
164.
Durack D.T., Beeson P.B., Petersdorf R.G. Experimental bacterial endocarditis. 3. Production and progress of the disease in rabbits. Br. J. Exp. Pathol. 1973;54:142-151.
Not in our library
165.
Garrison P.K., Freedman L.R. Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart. Yale J. Biol. Med. 1970;42:394-410.
Not in our library
166.
Xiong Y.Q., Willard J., Yeaman M.R., Cheung A.L., Bayer A.S. Regulation of Staphylococcus aureus alpha-toxin gene (hla) expression by agr, sarA, and sae In vitro and in experimental infective endocarditis. J. Infect. Dis. 2006;194:1267-1275.
Not in our library10.1086/508210
167.
Dubee V., Chau F., Arthur M., Garry L., Benadda S., Mesnage S., Lefort A., Fantin B. The In vitro contribution of autolysins to bacterial killing elicited by amoxicillin increases with inoculum size in Enterococcus faecalis. Antimicrob. Agents Chemother. 2011;55:910-912.
Not in our library10.1128/aac.01230-10
168.
Frehel C., Hellio R., Cremieux A.C., Contrepois A., Bouvet A. Nutritionally variant streptococci develop ultrastructural abnormalities during experimental endocarditis. Microbial. Pathog. 1988;4:247-255.
Not in our library10.1016/0882-4010(88)90085-x
169.
Veloso T.R., Amiguet M., Rousson V., Giddey M., Vouillamoz J., Moreillon P., Entenza J.M. Induction of experimental endocarditis by continuous low-grade bacteremia mimicking spontaneous bacteremia in humans. Infect. Immun. 2011;79:2006-2011.
Not in our library10.1128/iai.01208-10
170.
Veloso T.R., Chaouch A., Roger T., Giddey M., Vouillamoz J., Majcherczyk P., Que Y.A., Rousson V., Moreillon P., Entenza J.M. Use of a human-like low-grade bacteremia model of experimental endocarditis to study the role of Staphylococcus aureus adhesins and platelet aggregation in early endocarditis. Infect. Immun. 2013;81:697-703.
Not in our library10.1128/iai.01030-12
171.
Ambrose P.G., Drusano G.L., Craig W.A. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2012;54(Suppl 3):S220-228.
Not in our library10.1093/cid/cis001
172.
Seidl K., Chen L., Bayer A.S., Hady W.A., Kreiswirth B.N., Xiong Y.Q. Relationship of agr expression and function with virulence and vancomycin treatment outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2011;55:5631-5639.
Not in our library10.1128/aac.05251-11
173.
Tattevin P., Saleh-Mghir A., Davido B., Ghout I., Massias L., Garcia de la Maria C., Miro J.M., Perronne C., Laurent F., Cremieux A.C. Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits. Antimicrob. Agents Chemother. 2013;57:1157-1162.
Not in our library10.1128/aac.01669-12
174.
Hall-Stoodley L., Hu F.Z., Gieseke A., Nistico L., Nguyen D., Hayes J., Forbes M., Greenberg D.P., Dice B., Burrows A., et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA. 2006;296:202-211.
Not in our library10.1001/jama.296.2.202
175.
Bakaletz L.O. Bacterial biofilms in the upper airway - evidence for role in pathology and implications for treatment of otitis media. Paediatr. Respir. Rev. 2012;13:154-159.
Not in our library10.1016/j.prrv.2012.03.001
176.
Bakaletz L.O. Chinchilla as a robust, reproducible and polymicrobial model of otitis media and its prevention. Expert Rev. Vaccines. 2009;8:1063-1082.
Not in our library10.1586/erv.09.63
177.
Silva R.C., Dohar J.E., Hebda P.A. Novel rat model of tympanostomy tube otorrhea. Int. J. Pediatr. Otorhinolaryngol. 2012;76:179-182.
Not in our library10.1016/j.ijporl.2011.11.001
178.
Trune D.R., Zheng Q.Y. Mouse models for human otitis media. Brain Res. 2009;1277:90-103.
Not in our library10.1016/j.brainres.2009.02.047
179.
Giebink G.S. Immunoprophylaxis of otitis media. Adv. Exp. Med. Biol. 1991;303:149-158.
Not in our library10.1007/978-1-4684-6000-1_16
180.
Giebink G.S., Payne E.E., Mills E.L., Juhn S.K., Quie P.G. Experimental otitis media due to Streptococcus pneumoniae: immunopathogenic response in the chinchilla. J. Infect. Dis. 1976;134:595-604.
Not in our library10.1093/infdis/134.6.595
181.
Juhn S.K., Giebink G.S., Hanson D.G., Paparella M.M. Experimentally induced acute otitis media--an animal model. Arch. Otorhinolaryngol. 1977;215:95-96.
Not in our library10.1007/bf00463197
182.
Jurcisek J.A., Durbin J.E., Kusewitt D.F., Bakaletz L.O. Anatomy of the nasal cavity in the chinchilla. Cells Tissues Organs. 2003;174:136-152.
Not in our library10.1159/000071154
183.
Ehrlich G.D., Veeh R., Wang X., Costerton J.W., Hayes J.D., Hu F.Z., Daigle B.J., Ehrlich M.D., Post J.C. Mucosal biofilm formation on middle-ear mucosa in the chinchilla model of otitis media. JAMA. 2002;287:1710-1715.
Not in our library10.1001/jama.287.13.1710
184.
Post J.C. Direct evidence of bacterial biofilms in otitis media. Laryngoscope. 2001;111:2083-2094.
Not in our library10.1097/00005537-200112000-00001
185.
Roberts A.L., Connolly K.L., Doern C.D., Holder R.C., Reid S.D. Loss of the group A Streptococcus regulator Srv decreases biofilm formation in vivo in an otitis media model of infection. Infect. Immun. 2010;78:4800-4808.
Not in our library10.1128/iai.00255-10
186.
Byrd M.S., Pang B., Hong W., Waligora E.A., Juneau R.A., Armbruster C.E., Weimer K.E., Murrah K., Mann E.E., Lu H., et al. Direct evaluation of Pseudomonas aeruginosa biofilm mediators in a chronic infection model. Infect. Immun. 2011;79:3087-3095.
Not in our library10.1128/iai.00057-11
187.
Bhutta M.F. Mouse models of otitis media: strengths and limitations. Otolaryngol. Head Neck Surg. 2012;147:611-614.
Not in our library10.1177/0194599812449986
188.
Briles D.E., Hollingshead S.K., Nabors G.S., Paton J.C., Brooks-Walter A. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine. 2000;19(Suppl 1):S87-95.
Not in our library10.1016/s0264-410x(00)00285-1
189.
Holmes A.R., McNab R., Millsap K.W., Rohde M., Hammerschmidt S., Mawdsley J.L., Jenkinson H.F. The pavA gene of Streptococcus pneumoniae encodes a fibronectin-binding protein that is essential for virulence. Mol. Microbiol. 2001;41:1395-1408.
Not in our library10.1046/j.1365-2958.2001.02610.x
190.
Dohar J.E., Hebda P.A., Veeh R., Awad M., Costerton J.W., Hayes J., Ehrlich G.D. Mucosal biofilm formation on middle-ear mucosa in a nonhuman primate model of chronic suppurative otitis media. Laryngoscope. 2005;115:1469-1472.
Not in our library10.1097/01.mlg.0000172036.82897.d4
191.
Chaney E.J., Nguyen C.T., Boppart S.A. Novel method for non-invasive induction of a middle-ear biofilm in the rat. Vaccine. 2011;29:1628-1633.
Not in our library10.1016/j.vaccine.2010.12.076
192.
Eriksson P.O., Li J., Ny T., Hellstrom S. Spontaneous development of otitis media in plasminogen-deficient mice. Int. J. Med. Microbiol. 2006;296:501-509.
Not in our library10.1016/j.ijmm.2006.04.002
193.
Ferguson B.J., Stolz D.B. Demonstration of biofilm in human bacterial chronic rhinosinusitis. Am. J. Rhinol. 2005;19:452-457.
Not in our library
194.
Harvey R.J., Lund V.J. Biofilms and chronic rhinosinusitis: systematic review of evidence, current concepts and directions for research. Rhinology. 2007;45:3-13.
Not in our library
195.
Johansson P., Kumlien J., Carlsoo B., Drettner B., Nord C.E. Experimental acute sinusitis in rabbits. A bacteriological and histological study. Acta Otolaryngol. 1988;105:357-366.
Not in our library10.3109/00016488809097019
196.
Westrin K.M., Norlander T., Stierna P., Carlsoo B., Nord C.E. Experimental maxillary sinusitis induced by Bacteroides fragilis. A bacteriological and histological study in rabbits. Acta Otolaryngol. 1992;112:107-114.
Not in our library10.3109/00016489209100791
197.
Abreu N.A., Nagalingam N.A., Song Y., Roediger F.C., Pletcher S.D., Goldberg A.N., Lynch S.V. Sinus microbiome diversity depletion and Corynebacterium tuberculostearicum enrichment mediates rhinosinusitis. Sci. Transl. Med. 2012;4:151ra124.
Not in our library10.1126/scitranslmed.3003783
198.
Ha K.R., Psaltis A.J., Tan L., Wormald P.J. A sheep model for the study of biofilms in rhinosinusitis. Am. J. Rhinol. 2007;21:339-345.
Not in our library10.2500/ajr.2007.21.3032
199.
Le T., Psaltis A., Tan L.W., Wormald P.J. The efficacy of topical antibiofilm agents in a sheep model of rhinosinusitis. Am. J. Rhinol. 2008;22:560-567.
Not in our library10.2500/ajr.2008.22.3232
200.
Huang R., Li M., Gregory R.L. Bacterial interactions in dental biofilm. Virulence. 2011;2:435-444.
Not in our library10.4161/viru.2.5.16140
201.
Kolenbrander P.E., Andersen R.N., Kazmerzak K., Wu R., Palmer R.J. Spatial organization of oral bacteria in biofilms. Methods Enzymol. 1999;310:322-332.
Not in our library10.1016/s0076-6879(99)10026-0
202.
Kolenbrander P.E. Multispecies communities: interspecies interactions influence growth on saliva as sole nutritional source. Int. J. Oral. Sci. 2011;3:49-54.
Not in our library10.4248/ijos11025
203.
Quivey R.G., Kuhnert W.L., Hahn K. Adaptation of oral streptococci to low pH. Adv. Microb. Physiol. 2000;42:239-274.
Not in our library10.1016/s0065-2911(00)42004-7
204.
Bowen W.H., Schilling K., Giertsen E., Pearson S., Lee S.F., Bleiweis A., Beeman D. Role of a cell surface-associated protein in adherence and dental caries. Infect. Immun. 1991;59:4606-4609.
Not in our library10.1128/iai.59.12.4606-4609.1991
205.
Catalan M.A., Scott-Anne K., Klein M.I., Koo H., Bowen W.H., Melvin J.E. Elevated incidence of dental caries in a mouse model of cystic fibrosis. PLoS One. 2011;6:e16549.
Not in our library10.1371/journal.pone.0016549
206.
Fitzgerald R.J., Keyes P.H. Demonstration of the etiologic role of streptococci in experimental caries in the hamster. J. Am. Dent. Assoc. 1960;61:9-19.
Not in our library10.14219/jada.archive.1960.0138
207.
Bainbridge B., Verma R.K., Eastman C., Yehia B., Rivera M., Moffatt C., Bhattacharyya I., Lamont R.J., Kesavalu L. Role of Porphyromonas gingivalis phosphoserine phosphatase enzyme SerB in inflammation, immune response, and induction of alveolar bone resorption in rat. Infect. Immun. 2010;78:4560-4569.
Not in our library10.1128/iai.00703-10
208.
Okada Y., Hamada N., Kim Y., Takahashi Y., Sasaguri K., Ozono S., Sato S. Blockade of sympathetic beta-receptors inhibits Porphyromonas gingivalis-induced alveolar bone loss in an experimental rat periodontitis model. Archives of oral biology. 2010;55:502-508.
Not in our library10.1016/j.archoralbio.2010.04.002
209.
Koo H., Duarte S., Murata R.M., Scott-Anne K., Gregoire S., Watson G.E., Singh A.P., Vorsa N. Influence of cranberry proanthocyanidins on formation of biofilms by Streptococcus mutans on saliva-coated apatitic surface and on dental caries development in vivo. Caries Res. 2010;44:116-126.
Not in our library10.1159/000296306
210.
Koo H., Schobel B., Scott-Anne K., Watson G., Bowen W.H., Cury J.A., Rosalen P.L., Park Y.K. Apigenin and tt-farnesol with fluoride effects on S. mutans biofilms and dental caries. J. Dent. Res. 2005;84:1016-1020.
Not in our library10.1177/154405910508401109
211.
Assuma R., Oates T., Cochran D., Amar S., Graves D.T. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J. Immunol. 1998;160:403-409.
Not in our library
212.
Graves D.T., Kang J., Andriankaja O., Wada K., Rossa C. Animal models to study host-bacteria interactions involved in periodontitis. Front. Oral. Biol. 2012;15:117-132.
Not in our library10.1159/000329675
213.
Socransky S.S., Haffajee A.D., Cugini M.A., Smith C., Kent R.L. Microbial complexes in subgingival plaque. J. Clin. Periodontol. 1998;25:134-144.
Not in our library10.1111/j.1600-051x.1998.tb02419.x
214.
Madden T.E., Caton J.G. Animal models for periodontal disease. Methods Enzymol. 1994;235:106-119.
Not in our library10.1016/0076-6879(94)35135-x
215.
Struillou X., Boutigny H., Soueidan A., Layrolle P. Experimental animal models in periodontology: a review. Open Dent. J. 2010;4:37-47.
Not in our library10.2174/1874210601004010037
216.
Giannobile W.V., Finkelman R.D., Lynch S.E. Comparison of canine and non-human primate animal models for periodontal regenerative therapy: results following a single administration of PDGF/IGF-I. J. Periodontol. 1994;65:1158-1168.
Not in our library10.1902/jop.1994.65.12.1158
217.
Page R.C., Schroeder H.E., Pub S.K. Periodontitis in Man and Other Animals: A Comparative Review. 1982;300.
Not in our library
218.
Schou S., Holmstrup P., Reibel J., Juhl M., Hjorting-Hansen E., Kornman K.S. Ligature-induced marginal inflammation around osseointegrated implants and ankylosed teeth: stereologic and histologic observations in cynomolgus monkeys (Macaca fascicularis). J. Periodontol. 1993;64:529-537.
Not in our library10.1902/jop.1993.64.6.529
219.
Yamasaki A., Nikai H., Niitani K., Ijuhin N. Ultrastructure of the junctional epithelium of germfree rat gingiva. J. Periodontol. 1979;50:641-648.
Not in our library10.1902/jop.1979.50.12.641
220.
Baker P.J., Evans R.T., Roopenian D.C. Oral infection with Porphyromonas gingivalis and induced alveolar bone loss in immunocompetent and severe combined immunodeficient mice. Arch. Oral. Biol. 1994;39:1035-1040.
Not in our library10.1016/0003-9969(94)90055-8
221.
Myneni S.R., Settem R.P., Connell T.D., Keegan A.D., Gaffen S.L., Sharma A. TLR2 signaling and Th2 responses drive Tannerella forsythia-induced periodontal bone loss. J. Immunol. 2011;187:501-509.
Not in our library10.4049/jimmunol.1100683
222.
Settem R.P., El-Hassan A.T., Honma K., Stafford G.P., Sharma A. Fusobacterium nucleatum and Tannerella forsythia induce synergistic alveolar bone loss in a mouse periodontitis model. Infect. Immun. 2012;80:2436-2443.
Not in our library10.1128/iai.06276-11
223.
Lee S.F., Andrian E., Rowland E., Marquez I.C. Immune response and alveolar bone resorption in a mouse model of Treponema denticola infection. Infect. Immun. 2009;77:694-698.
Not in our library10.1128/iai.01004-08
224.
Polak D., Wilensky A., Shapira L., Halabi A., Goldstein D., Weiss E.I., Houri-Haddad Y. Mouse model of experimental periodontitis induced by Porphyromonas gingivalis/Fusobacterium nucleatum infection: bone loss and host response. J. Clin. Periodontol. 2009;36:406-410.
Not in our library10.1111/j.1600-051x.2009.01393.x
225.
Schwab J.M., Chiang N., Arita M., Serhan C.N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007;447:869-874.
Not in our library10.1038/nature05877
226.
Tsukayama D.T. Pathophysiology of posttraumatic osteomyelitis. Clin. Orthop. Relat. Res. 1999;360:22-29.
Not in our library10.1097/00003086-199903000-00005
227.
Gristina A.G., Oga M., Webb L.X., Hobgood C.D. Adherent bacterial colonization in the pathogenesis of osteomyelitis. Science. 1985;228:990-993.
Not in our library10.1126/science.4001933
228.
Marrie T.J., Costerton J.W. Mode of growth of bacterial pathogens in chronic polymicrobial human osteomyelitis. J. Clin. Microbiol. 1985;22:924-933.
Not in our library10.1128/jcm.22.6.924-933.1985
229.
Scheman L., Janot M., Lewin P. The production of experimental osteomyelitis: prelimary report. JAMA. 1941;117:1525-1529.
Not in our library
230.
Mader J.T., Shirtliff M.E., Bergquist S.C., Calhoun J. Antimicrobial treatment of chronic osteomyelitis. Clin. Orthop. Relat. Res. 1999;47-65.
Not in our library10.1097/00003086-199903000-00008
231.
Brady R.A., Leid J.G., Camper A.K., Costerton J.W., Shirtliff M.E. Identification of Staphylococcus aureus proteins recognized by the antibody-mediated immune response to a biofilm infection. Infect. Immun. 2006;74:3415-3426.
Not in our library10.1128/iai.00392-06
232.
Brady R.A., O'May G.A., Leid J.G., Prior M.L., Costerton J.W., Shirtliff M.E. Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect. Immun. 2011;79:1797-1803.
Not in our library10.1128/iai.00451-10
233.
Poeppl W., Tobudic S., Lingscheid T., Plasenzotti R., Kozakowski N., Lagler H., Georgopoulos A., Burgmann H. Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat mode. Antimicrob. Agents Chemother. 2011;55:4999-5003.
Not in our library10.1128/aac.00584-11
234.
Funao H., Ishii K., Nagai S., Sasaki A., Hoshikawa T., Aizawa M., Okada Y., Chiba K., Koyasu S., Toyama Y., et al. Establishment of a real-time, quantitative, and reproducible mouse model of Staphylococcus osteomyelitis using bioluminescence imaging. Infect. Immun. 2012;80:733-741.
Not in our library10.1128/iai.06166-11
235.
Marrie T.J., Nelligan J., Costerton J.W. A scanning and transmission electron microscopic study of an infected endocardial pacemaker lead. Circulation. 1982;66:1339-1341.
Not in our library10.1161/01.cir.66.6.1339
236.
Lewis K. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 2007;5:48-56.
Not in our library10.1038/nrmicro1557
237.
Christensen G.D., Simpson W.A., Bisno A.L., Beachey E.H. Experimental foreign body infections in mice challenged with slime-producing Staphylococcus epidermidis. Infect. Immun. 1983;40:407-410.
Not in our library10.1128/iai.40.1.407-410.1983
238.
Nickel J.C., Grant S.K., Costerton J.W. Catheter-associated bacteriuria. An experimental study. Urology. 1985;26:369-375.
Not in our library10.1016/0090-4295(85)90185-2
239.
Rupp M.E., Ulphani J.S., Fey P.D., Mack D. Characterization of Staphylococcus epidermidis polysaccharide intercellular adhesin/hemagglutinin in the pathogenesis of intravascular catheter-associated infection in a rat model. Infect. Immun. 1999;67:2656-2659.
Not in our library10.1128/iai.67.5.2656-2659.1999
240.
Zimmerli W., Waldvogel F.A., Vaudaux P., Nydegger U.E. Pathogenesis of foreign body infection: description and characteristics of an animal model. J. Infect. Dis. 1982;146:487-497.
Not in our library10.1093/infdis/146.4.487
241.
Christensen G.D., Bisno A.L., Parisi J.T., McLaughlin B., Hester M.G., Luther R.W. Nosocomial septicemia due to multiply antibiotic-resistant Staphylococcus epidermidis. Ann. Intern. Med. 1982;96:1-10.
Not in our library10.7326/0003-4819-96-1-1
242.
Christensen G.D., Simpson W.A., Bisno A.L., Beachey E.H. Adherence of slime-producing strains of Staphylococcus epidermidis to smooth surfaces. Infect. Immun. 1982;37:318-326.
Not in our library10.1128/iai.37.1.318-326.1982
243.
Rupp M.E., Fey P.D. In vivo models to evaluate adhesion and biofilm formation by Staphylococcus epidermidis. Methods Enzymol. 2001;336:206-215.
Not in our library10.1016/s0076-6879(01)36591-6
244.
Rupp M.E., Fey P.D., Heilmann C., Gotz F. Characterization of the importance of Staphylococcus epidermidis autolysin and polysaccharide intercellular adhesin in the pathogenesis of intravascular catheter-associated infection in a rat model. J. Infect. Dis. 2001;183:1038-1042.
Not in our library10.1086/319279
245.
Cirioni O., Giacometti A., Ghiselli R., Dell'Acqua G., Orlando F., Mocchegiani F., Silvestri C., Licci A., Saba V., Scalise G., et al. RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections. J. Infect. Dis. 2006;193:180-186.
Not in our library10.1086/498914
246.
Ebert T., Smith S., Pancari G., Wu X., Zorman J., Clark D., Cook J., Burns C., Antonello J.M., Cope L., et al. Development of a rat central venous catheter model for evaluation of vaccines to prevent Staphylococcus epidermidis and Staphylococcus aureus early biofilms. Hum. Vaccin. 2011;7:630-638.
Not in our library10.4161/hv.7.6.15407
247.
Hall L.L., DeLopez O.H., Roberts A., Smith F.A. A procedure for chronic intravenous catheterization in the rabbit. Lab. Anim. Sci. 1974;24:79-83.
Not in our library
248.
Kokai-Kun J.F., Chanturiya T., Mond J.J. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. J. Antimicrob. Chemother. 2009;64:94-100.
Not in our library10.1093/jac/dkp145
249.
Giacometti A., Cirioni O., Ghiselli R., Orlando F., Mocchegiani F., Silvestri C., Licci A., De Fusco M., Provinciali M., Saba V., et al. Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. Antimicrob. Agents Chemother. 2005;49:4042-4045.
Not in our library10.1128/aac.49.10.4042-4045.2005
250.
Van Praagh A.D., Li T., Zhang S., Arya A., Chen L., Zhang X.X., Bertolami S., Mortin L.I. Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infections. Antimicrob. Agents Chemother. 2011;55:4081-4089.
Not in our library10.1128/aac.00147-11
251.
Capdevila J.A., Gavalda J., Fortea J., Lopez P., Martin M.T., Gomis X., Pahissa A. Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique. Clin. Microbiol. Infect. 2001;7:206-212.
Not in our library10.1046/j.1469-0691.2001.00233.x
252.
Fernandez-Hidalgo N., Gavalda J., Almirante B., Martin M.T., Onrubia P.L., Gomis X., Pahissa A. Evaluation of linezolid, vancomycin, gentamicin and ciprofloxacin in a rabbit model of antibiotic-lock technique for Staphylococcus aureus catheter-related infection. J. Antimicrob. Chemother. 2010;65:525-530.
Not in our library10.1093/jac/dkp499
253.
Raad I., Hachem R., Tcholakian R.K., Sherertz R. Efficacy of minocycline and EDTA lock solution in preventing catheter-related bacteremia, septic phlebitis, and endocarditis in rabbit. Antimicrob. Agents Chemother. 2002;46:327-332.
Not in our library10.1128/aac.46.2.327-332.2002
254.
Del Pozo J.L., Rodil R., Aguinaga A., Yuste J.R., Bustos C., Montero A., Espinosa G., Garcia-Fernandez N. Daptomycin lock therapy for grampositive long-term catheter-related bloodstream infections. Int. J. Clin. Pract. 2012;66:305-308.
Not in our library10.1111/j.1742-1241.2011.02830.x
255.
Raad I.I., Fang X., Keutgen X.M., Jiang Y., Sherertz R., Hachem R. The role of chelators in preventing biofilm formation and catheter-related bloodstream infections. Curr. Opin. Infect. Dis. 2008;21:385-392.
Not in our library10.1097/qco.0b013e32830634d8
256.
Chauhan A., Lebeaux D., Decante B., Kriegel I., Escande M.C., Ghigo J.M., Beloin C. A rat model of central venous catheter to study establishment of long-term bacterial biofilm and related acute and chronic infections. PLoS One. 2012;7:e37281.
Not in our library10.1371/journal.pone.0037281
257.
Chauhan A., Lebeaux D., Ghigo J.M., Beloin C. Full and broad-spectrum in vivo eradication of catheter-associated biofilms using gentamicin-EDTA antibiotic lock therapy. Antimicrob. Agents Chemother. 2012;56:6310-6318.
Not in our library10.1128/aac.01606-12
258.
Jones R.F., Young P.S., Marosszeky J.E. Treatment of infection in the presence of an indwelling urethral catheter. Br. J. Urol. 1982;54:316-319.
Not in our library10.1111/j.1464-410x.1982.tb06987.x
259.
Nickel J.C., Gristina A.G., Costerton J.W. Electron microscopic study of an infected Foley catheter. Can. J. Surg. 1985;28:50-51.
Not in our library
260.
Haraoka M., Matsumoto T., Takahashi K., Kubo S., Tanaka M., Kumazawa J. Effect of prednisolone on ascending renal infection due to biofilm disease and lower urinary tract obstruction in rats. Urol. Res. 1995;22:383-387.
Not in our library10.1007/bf00296880
261.
Cirioni O., Ghiselli R., Silvestri C., Minardi D., Gabrielli E., Orlando F., Rimini M., Brescini L., Muzzonigro G., Guerrieri M., et al. Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection. J. Antimicrob. Chemother. 2011;66:1318-1323.
Not in our library10.1093/jac/dkr107
262.
Allison K.R., Brynildsen M.P., Collins J.J. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature. 2011;473:216-220.
Not in our library10.1038/nature10069
263.
Fung L.C., Mittelman M.W., Thorner P.S., Khoury A.E. A novel rabbit model for the evaluation of biomaterial associated urinary tract infection. Can. J. Urol. 2003;10:2007-2012.
Not in our library
264.
Guiton P.S., Hung C.S., Hancock L.E., Caparon M.G., Hultgren S.J. Enterococcal biofilm formation and virulence in an optimized murine model of foreign body-associated urinary tract infections. Infect. Immun. 2010;78:4166-4175.
Not in our library10.1128/iai.00711-10
265.
Cadieux P.A., Chew B.H., Knudsen B.E., Dejong K., Rowe E., Reid G., Denstedt J.D. Triclosan loaded ureteral stents decrease Proteus mirabilis 296 infection in a rabbit urinary tract infection model. J. Urol. 2006;175:2331-2335.
Not in our library10.1016/s0022-5347(06)00252-7
266.
Kadurugamuwa J.L., Modi K., Yu J., Francis K.P., Purchio T., Contag P.R. Noninvasive biophotonic imaging for monitoring of catheter-associated urinary tract infections and therapy in mice. Infect. Immun. 2005;73:3878-3887.
Not in our library10.1128/iai.73.7.3878-3887.2005
267.
Guiton P.S., Cusumano C.K., Kline K.A., Dodson K.W., Han Z., Janetka J.W., Henderson J.P., Caparon M.G., Hultgren S.J. Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. Antimicrob. Agents Chemother. 2012;56:4738-4745.
Not in our library10.1128/aac.00447-12
268.
Morck D.W., Lam K., McKay S.G., Olson M.E., Prosser B., Ellis B.D., Cleeland R., Costerton J.W. Comparative evaluation of fleroxacin, ampicillin, trimethoprimsulfamethoxazole, and gentamicin as treatments of catheter-associated urinary tract infection in a rabbit model. Int. J. Antimicrob. Agents. 1994;4(Suppl 2):S21-S27.
Not in our library10.1016/0924-8579(94)90018-3
269.
Olson M.E., Nickel J.C., Khoury A.E., Morck D.W., Cleeland R., Costerton J.W. Amdinocillin treatment of catheter-associated bacteriuria in rabbits. J. Infect. Dis. 1989;159:1065-1072.
Not in our library10.1093/infdis/159.6.1065
270.
Hachem R., Reitzel R., Borne A., Jiang Y., Tinkey P., Uthamanthil R., Chandra J., Ghannoum M., Raad I. Novel antiseptic urinary catheters for prevention of urinary tract infections: correlation of in vivo and In vitro test results. Antimicrob. Agents Chemother. 2009;53:5145-5149.
Not in our library10.1128/aac.00718-09
271.
Hazan Z., Zumeris J., Jacob H., Raskin H., Kratysh G., Vishnia M., Dror N., Barliya T., Mandel M., Lavie G. Effective prevention of microbial biofilm formation on medical devices by low-energy surface acoustic waves. Antimicrob. Agents Chemother. 2006;50:4144-4152.
Not in our library10.1128/aac.00418-06
272.
Davis C.P., Shirtliff M.E., Scimeca J.M., Hoskins S.L., Warren M.M. In vivo reduction of bacterial populations in the urinary tract of catheterized sheep by iontophoresis. J Urol. 1995;154:1948-1953.
Not in our library
273.
Pickard R., Lam T., MacLennan G., Starr K., Kilonzo M., McPherson G., Gillies K., McDonald A., Walton K., Buckley B., et al. Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial. Lancet. 2012;380:1927-1935.
Not in our library10.1016/s0140-6736(12)61380-4
274.
Rodet A. Physiologie pathologique - étude expérimentale sur l’ostéomyelite infectieuse. C R Acad. Sci. 1885;99:569-571.
Not in our library
275.
Andriole V.T., Nagel D.A., Southwick W.O. A paradigm for human chronic osteomyelitis. J. Bone Joint Surg. Am. 1973;55:1511-1515.
Not in our library
276.
Gristina A.G., Costerton J.W. Bacterial adherence and the glycocalyx and their role in musculoskeletal infection. Orthop. Clin. North. Am. 1984;15:517-535.
Not in our library
277.
Mayberry-Carson K.J., Tober-Meyer B., Smith J.K., Lambe D.W., Costerton J.W. Bacterial adherence and glycocalyx formation in osteomyelitis experimentally induced with Staphylococcus aureus. Infect. Immun. 1984;43:825-833.
Not in our library10.1128/iai.43.3.825-833.1984
278.
Petty W., Spanier S., Shuster J.J., Silverthorne C. The influence of skeletal implants on incidence of infection. Experiments in a canine model. J. Bone Joint Surg. Am. 1985;67:1236-1244.
Not in our library
279.
Sanzen L., Linder L. Infection adjacent to titanium and bone cement implants: an experimental study in rabbits. Biomaterials. 1995;16:1273-1277.
Not in our library10.1016/0142-9612(95)98136-3
280.
Evans R.P., Nelson C.L., Harrison B.H. The effect of wound environment on the incidence of acute osteomyelitis. Clin. Orthop. Relat. Res. 1993;289-297.
Not in our library
281.
Prabhakara R., Harro J.M., Leid J.G., Keegan A.D., Prior M.L., Shirtliff M.E. Suppression of the inflammatory immune response prevents the development of chronic biofilm infection due to methicillin-resistant Staphylococcus aureus. Infect. Immun. 2011;79:5010-5018.
Not in our library10.1128/iai.05571-11
282.
Lucke M., Schmidmaier G., Sadoni S., Wildemann B., Schiller R., Haas N.P., Raschke M. Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats. Bone. 2003;32:521-531.
Not in our library10.1016/s8756-3282(03)00050-4
283.
Lucke M., Wildemann B., Sadoni S., Surke C., Schiller R., Stemberger A., Raschke M., Haas N.P., Schmidmaier G. Systemic versus local application of gentamicin in prophylaxis of implant-related osteomyelitis in a rat model. Bone. 2005;36:770-778.
Not in our library10.1016/j.bone.2005.01.008
284.
Fitzgerald R.H. Experimental osteomyelitis: description of a canine model and the role of depot administration of antibiotics in the prevention and treatment of sepsis. J. Bone Joint Surg. Am. 1983;65:371-380.
Not in our library
285.
Fuchs T., Stange R., Schmidmaier G., Raschke M.J. The use of gentamicin-coated nails in the tibia: preliminary results of a prospective study. Arch. Orthop. Trauma Surg. 2011;131:1419-1425.
Not in our library10.1007/s00402-011-1321-6
286.
Belmatoug N., Cremieux A.C., Bleton R., Volk A., Saleh-Mghir A., Grossin M., Garry L., Carbon C. A new model of experimental prosthetic joint infection due to methicillin-resistant Staphylococcus aureus: a microbiologic, histopathologic, and magnetic resonance imaging characterization. J. Infect. Dis. 1996;174:414-417.
Not in our library10.1093/infdis/174.2.414
287.
Schurman D.J., Trindade C., Hirshman H.P., Moser K., Kajiyama G., Stevens P. Antibiotic-acrylic bone cement composites. Studies of gentamicin and Palacos. J. Bone Joint Surg. Am. 1978;60:978-984.
Not in our library
288.
Blomgren G., Lindgren U. Late hematogenous infection in total joint replacement: studies of gentamicin and bone cement in the rabbit. Clin. Orthop. Relat. Res. 1981;244-248.
Not in our library
289.
A Mouse Model of Post-Arthroplasty Staphylococcus aureus Joint Infection to Evaluate In Vivo the Efficacy of Antimicrobial Implant Coatings · 2010
No notice
290.
Cremieux A.C., Mghir A.S., Bleton R., Manteau M., Belmatoug N., Massias L., Garry L., Sales N., Maziere B., Carbon C. Efficacy of sparfloxacin and autoradiographic diffusion pattern of [14C]Sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob. Agents Chemother. 1996;40:2111-2116.
Not in our library10.1128/aac.40.9.2111
291.
Inglis T.J., Millar M.R., Jones J.G., Robinson D.A. Tracheal tube biofilm as a source of bacterial colonization of the lung. J. Clin. Microbiol. 1989;27:2014-2018.
Not in our library10.1128/jcm.27.9.2014-2018.1989
292.
Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept · 2012
No notice
293.
Berra L., De Marchi L., Yu Z.X., Laquerriere P., Baccarelli A., Kolobow T. Endotracheal tubes coated with antiseptics decrease bacterial colonization of the ventilator circuits, lungs, and endotracheal tube. Anesthesiology. 2004;100:1446-1456.
Not in our library10.1097/00000542-200406000-00017
294.
Fernandez-Barat L., Li Bassi G., Ferrer M., Bosch A., Calvo M., Vila J., Gabarrus A., Martinez-Olondris P., Rigol M., Esperatti M., et al. Direct analysis of bacterial viability in endotracheal tube biofilm from a pig model of methicillin-resistant Staphylococcus aureus pneumonia following antimicrobial therapy. FEMS Immunol. Med. Microbiol. 2012;65:309-317.
Not in our library10.1111/j.1574-695x.2012.00961.x
295.
Olson M.E., Harmon B.G., Kollef M.H. Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs. Chest. 2002;121:863-870.
Not in our library10.1378/chest.121.3.863
296.
Kollef M.H., Afessa B., Anzueto A., Veremakis C., Kerr K.M., Margolis B.D., Craven D.E., Roberts P.R., Arroliga A.C., Hubmayr R.D., et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA. 2008;300:805-813.
Not in our library10.1001/jama.300.7.805
297.
Berra L., Curto F., Li Bassi G., Laquerriere P., Baccarelli A., Kolobow T. Antibacterial-coated tracheal tubes cleaned with the Mucus Shaver: a novel method to retain long-term bactericidal activity of coated tracheal tubes. Intensive Care Med. 2006;32:888-893.
Not in our library10.1007/s00134-006-0125-6
298.
Berra L., Coppadoro A., Bittner E.A., Kolobow T., Laquerriere P., Pohlmann J.R., Bramati S., Moss J., Pesenti A. A clinical assessment of the Mucus Shaver: a device to keep the endotracheal tube free from secretions. Crit. Care Med. 2012;40:119-124.
Not in our library10.1097/ccm.0b013e31822e9fe3
299.
Fernandez-Barat L., Ferrer M., Sierra J.M., Soy D., Guerrero L., Vila J., Li Bassi G., Cortadellas N., Martinez-Olondris P., Rigol M., et al. Linezolid limits burden of methicillin-resistant Staphylococcus aureus in biofilm of tracheal tubes. Crit. Care Med. 2012;40:2385-2389.
Not in our library10.1097/ccm.0b013e31825332fc
300.
Tollefson D.F., Bandyk D.F., Kaebnick H.W., Seabrook G.R., Towne J.B. Surface biofilm disruption. Enhanced recovery of microorganisms from vascular prostheses. Arch. Surg. 1987;122:38-43.
Not in our library10.1001/archsurg.1987.01400130044006
301.
Gahtan V., Esses G.E., Bandyk D.F., Nelson R.T., Dupont E., Mills J.L. Antistaphylococcal activity of rifampin-bonded gelatin-impregnated Dacron grafts. J. Surg. Res. 1995;58:105-110.
Not in our library10.1006/jsre.1995.1017
302.
Gao H., Sandermann J., Prag J., Lund L., Lindholt J.S. Rifampicin-soaked silver polyester versus expanded polytetrafluoro-ethylene grafts for in situ replacement of infected grafts in a porcine randomised controlled trial. Eur. J. Vasc. Endovasc. Surg. 2012;43:582-587.
Not in our library10.1016/j.ejvs.2012.02.011
303.
Aboshady I., Raad I., Shah A.S., Vela D., Dvorak T., Safi H.J., Buja L.M., Khalil K.G. A pilot study of a triple antimicrobial-bonded Dacron graft for the prevention of aortic graft infection. J. Vasc. Surg. 2012;56:794-801.
Not in our library10.1016/j.jvs.2012.02.008
304.
Lew W., Moore W. Antibiotic-impregnated grafts for aortic reconstruction. Semin. Vasc. Surg. 2011;24:211-219.
Not in our library10.1053/j.semvascsurg.2011.10.015
305.
Virden C.P., Dobke M.K., Stein P., Parsons C.L., Frank D.H. Subclinical infection of the silicone breast implant surface as a possible cause of capsular contracture. Aesthetic Plast Surg. 1992;16:173-179.
Not in our library10.1007/bf00450610
306.
Jacombs A., Allan J., Hu H., Valente P.M., Wessels W.L., Deva A.K., Vickery K. Prevention of biofilm-induced capsular contracture with antibiotic-impregnated mesh in a porcine model. Aesthet Surg. J. 2012;32:886-891.
Not in our library10.1177/1090820x12455429
307.
Tamboto H., Vickery K., Deva A.K. Subclinical (biofilm) infection causes capsular contracture in a porcine model following augmentation mammaplasty. Plast Reconstr. Surg. 2010;126:835-842.
Not in our library10.1097/prs.0b013e3181e3b456
308.
Slusher M.M., Myrvik Q.N., Lewis J.C., Gristina A.G. Extended-wear lenses, biofilm, and bacterial adhesion. Arch. Ophthalmol. 1987;105:110-115.
Not in our library10.1001/archopht.1987.01060010116042
309.
Szczotka-Flynn L.B., Pearlman E., Ghannoum M. Microbial contamination of contact lenses, lens care solutions, and their accessories: a literature review. Eye Contact Lens. 2010;36:116-129.
Not in our library10.1097/icl.0b013e3181d20cae
310.
Cole N., Hume E.B., Vijay A.K., Sankaridurg P., Kumar N., Willcox M.D. In vivo performance of melimine as an antimicrobial coating for contact lenses in models of CLARE and CLPU. Invest Ophthalmol. Vis Sci. 2010;51:390-395.
Not in our library10.1167/iovs.09-4068
311.
Sun Y., Chandra J., Mukherjee P., Szczotka-Flynn L., Ghannoum M.A., Pearlman E. A murine model of contact lens-associated Fusarium keratitis. Invest. Ophthalmol. Vis. Sci. 2010;51:1511-1516.
Not in our library10.1167/iovs.09-4237
312.
Wood S.R., Kirkham J., Marsh P.D., Shore R.C., Nattress B., Robinson C. Architecture of intact natural human plaque biofilms studied by confocal laser scanning microscopy. J. Dental Res. 2000;79:21-27.
Not in our library10.1177/00220345000790010201
313.
Berglundh T., Lindhe J., Marinello C., Ericsson I., Liljenberg B. Soft tissue reaction to de novo plaque formation on implants and teeth. An experimental study in the dog. Clin. Oral. Implants Res. 1992;3:1-8.
Not in our library10.1034/j.1600-0501.1992.030101.x
314.
Albouy J.P., Abrahamsson I., Berglundh T. Spontaneous progression of experimental peri-implantitis at implants with different surface characteristics: an experimental study in dogs. J. Clin. Periodontol. 2012;39:182-187.
Not in our library10.1111/j.1600-051x.2011.01820.x
315.
Freire M.O., Sedghizadeh P.P., Schaudinn C., Gorur A., Downey J.S., Choi J.H., Chen W., Kook J.K., Chen C., Goodman S.D., et al. Development of an animal model for Aggregatibacteractinomycetemcomitans biofilm-mediated oral osteolytic infection: a preliminary study. J. Periodontol. 2011;82:778-789.
Not in our library10.1902/jop.2010.100263
316.
Rimondini L., Fare S., Brambilla E., Felloni A., Consonni C., Brossa F., Carrassi A. The effect of surface roughness on early in vivo plaque colonization on titanium. J. Periodontol. 1997;68:556-562.
Not in our library10.1902/jop.1997.68.6.556
317.
Scarano A., Piattelli M., Caputi S., Favero G.A., Piattelli A. Bacterial adhesion on commercially pure titanium and zirconium oxide disks: an in vivo human study. J. Periodontol. 2004;75:292-296.
Not in our library10.1902/jop.2004.75.2.292
318.
Garrigos C., Murillo O., Lora-Tamayo J., Verdaguer R., Tubau F., Cabellos C., Cabo J., Ariza J. Fosfomycin-Daptomycin and Other Fosfomycin Combinations as Alternative Therapies in Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2013;57:606-610.
Not in our library10.1128/aac.01570-12
319.
Zimmerli W., Widmer A.F., Blatter M., Frei R., Ochsner P.E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279:1537-1541.
Not in our library10.1001/jama.279.19.1537
320.
Zimmerli W. Experimental models in the investigation of device-related infections. J. Antimicrob. Chemother. 1993;31(Suppl D):97-102.
Not in our library10.1093/jac/31.suppl_d.97
321.
Beenken K.E., Dunman P.M., McAleese F., Macapagal D., Murphy E., Projan S.J., Blevins J.S., Smeltzer M.S. Global gene expression in Staphylococcus aureus biofilms. J. Bacteriol. 2004;186:4665-4684.
Not in our library10.1128/jb.186.14.4665-4684.2004
322.
Thurlow L.R., Hanke M.L., Fritz T., Angle A., Aldrich A., Williams S.H., Engebretsen I.L., Bayles K.W., Horswill A.R., Kielian T. Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo. J. Immunol. 2011;186:6585-6596.
Not in our library10.4049/jimmunol.1002794
323.
Weiss E.C., Zielinska A., Beenken K.E., Spencer H.J., Daily S.J., Smeltzer M.S. Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo. Antimicrob. Agents Chemother. 2009;53:4096-4102.
Not in our library10.1128/aac.00484-09
324.
Cobrado L., Silva-Dias A., Azevedo M.M., Pina-Vaz C., Rodrigues A.G. In vivo antibiofilm effect of cerium, chitosan and hamamelitannin against usual agents of catheter-related bloodstream infections. J. Antimicrob. Chemother. 2013;68:126-130.
Not in our library10.1093/jac/dks376
325.
Kadurugamuwa J.L., Sin L., Albert E., Yu J., Francis K., DeBoer M., Rubin M., Bellinger-Kawahara C., Parr Jr T.R., Contag P.R. Direct continuous method for monitoring biofilm infection in a mouse model. Infect. Immun. 2003;71:882-890.
Not in our library10.1128/iai.71.2.882-890.2003
326.
Raad I., Darouiche R., Hachem R., Mansouri M., Bodey G.P. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. J. Infect. Dis. 1996;173:418-424.
Not in our library10.1093/infdis/173.2.418
327.
Darouiche R.O., Raad I.I., Heard S.O., Thornby J.I., Wenker O.C., Gabrielli A., Berg J., Khardori N., Hanna H., Hachem R., et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N. Engl. J. Med. 1999;340:1-8.
Not in our library10.1056/nejm199901073400101
328.
Darouiche R.O., Mansouri M.D., Gawande P.V., Madhyastha S. Antimicrobial and antibiofilm efficacy of triclosan and DispersinB combination. J. Antimicrob. Chemother. 2009;64:88-93.
Not in our library10.1093/jac/dkp158
329.
Ensing G.T., Roeder B.L., Nelson J.L., van Horn J.R., van der Mei H.C., Busscher H.J., Pitt W.G. Effect of pulsed ultrasound in combination with gentamicin on bacterial viability in biofilms on bone cements in vivo. J. Appl. Microbiol. 2005;99:443-448.
Not in our library10.1111/j.1365-2672.2005.02643.x
330.
Hansen L.K., Brown M., Johnson D., Palme II D.F., Love C., Darouiche R. In vivo model of human pathogen infection and demonstration of efficacy by an antimicrobial pouch for pacing devices. Pacing Clin. Electrophysiol. 2009;32:898-907.
Not in our library10.1111/j.1540-8159.2009.02406.x
331.
Illingworth B.L., Tweden K., Schroeder R.F., Cameron J.D. In vivo efficacy of silver-coated (Silzone) infection-resistant polyester fabric against a biofilm-producing bacteria, Staphylococcus epidermidis. J. Heart Valve Dis. 1998;7:524-530.
Not in our library
332.
Illingworth B., Bianco R.W., Weisberg S. In vivo efficacy of silver-coated fabric against Staphylococcus epidermidis. J. Heart Valve Dis. 2000;9:135-141.
Not in our library
333.
Darouiche R.O., Meade R., Mansouri M., Raad I.I. In vivo efficacy of antimicrobial-coated fabric from prosthetic heart valve sewing rings. J. Heart Valve Dis. 1998;7:639-646.
Not in our library
334.
Darouiche R.O., Mansouri M.D., Meade R. In-vitro and in vivo activity of antimicrobial-coated prosthetic heart valve sewing cuffs. J. Heart Valve Dis. 2002;11:99-104.
Not in our library
335.
Nakamoto D.A., Rosenfield M.L., Haaga J.R., Merritt K., Sachs P.B., Hutton M.C., Graham R.C., Rowland D.Y. Young Investigator Award. In vivo treatment of infected prosthetic graft material with urokinase: an animal model. J. Vasc. Interv. Radiol. 1994;5:549-552.
Not in our library10.1016/s1051-0443(94)71552-9
336.
Garrison J.R., Henke P.K., Smith K.R., Brittian K.R., Lam T.M., Peyton J.C., Bergamini T.M. In vitro and in vivo effects of rifampin on Staphylococcus epidermidis graft infections. ASAIO J. 1997;43:8-12.
Not in our library
337.
Cirioni O., Mocchegiani F., Cacciatore I., Vecchiet J., Silvestri C., Baldassarre L., Ucciferri C., Orsetti E., Castelli P., Provinciali M., Vivarelli M., Fornasari E., Giacometti A. Quorum sensing inhibitor FS3-coated vascular graft enhances daptomycin efficacy in a rat model of staphylococcal infection. Peptides. 2013;40:77-81.
Not in our library10.1016/j.peptides.2012.12.002
338.
Rediske A.M., Roeder B.L., Nelson J.L., Robison R.L., Schaalje G.B., Robison R.A., Pitt W.G. Pulsed ultrasound enhances the killing of Escherichia coli biofilms by aminoglycoside antibiotics in vivo. Antimicrob. Agents Chemother. 2000;44:771-772.
Not in our library10.1128/aac.44.3.771-772.2000
339.
Anguita-Alonso P., Giacometti A., Cirioni O., Ghiselli R., Orlando F., Saba V., Scalise G., Sevo M., Tuzova M., Patel R., et al. RNAIII-inhibiting-peptide-loaded polymethylmethacrylate prevents in vivo Staphylococcus aureus biofilm formation. Antimicrob. Agents Chemother. 2007;51:2594-2596.
Not in our library10.1128/aac.00580-06
340.
Engelsman A.F., van Dam G.M., van der Mei H.C., Busscher H.J., Ploeg R.J. In vivo evaluation of bacterial infection involving morphologically different surgical meshes. Ann. Surg. 2010;251:133-137.
Not in our library10.1097/sla.0b013e3181b61d9a
341.
Daghighi S., Sjollema J., Jaspers V., de Boer L., Zaat S.A., Dijkstra R.J., van Dam G.M., van der Mei H.C., Busscher H.J. Persistence of a bioluminescent Staphylococcus aureus strain on and around degradable and non-degradable surgical meshes in a murine model. Acta Biomater. 2012;8:3991-3996.
Not in our library10.1016/j.actbio.2012.07.017
342.
Klionsky D.J., Abdalla F.C., Abeliovich H., Abraham R.T., Acevedo-Arozena A., Adeli K., Agholme L., Agnello M., Agostinis P., Aguirre-Ghiso J.A., et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8:445-544.
Not in our library10.4161/auto.19496
343.
Romero D., Kolter R. Will biofilm disassembly agents make it to market? Trends Microbiol. 2011;19:304-306.
Not in our library10.1016/j.tim.2011.03.003
344.
Von Herrath M.G., Nepom G.T. Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity. J. Exp. Med. 2005;202:1159-1162.
Not in our library10.1084/jem.20051224
345.
Warren H.S., Fitting C., Hoff E., Adib-Conquy M., Beasley-Topliffe L., Tesini B., Liang X., Valentine C., Hellman J., Hayden D., et al. Resilience to bacterial infection: difference between species could be due to proteins in serum. J. Infect. Dis. 2009;201:223-232.
Not in our library10.1086/649557
346.
Bolker J. Model organisms: There's more to life than rats and flies. Nature. 2012;491:31-33.
Not in our library10.1038/491031a
347.
Schnabel J. Neuroscience: Standard model. Nature. 2008;454:682-685.
Not in our library10.1038/454682a
348.
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research · 2010
No notice
349.
Madsen J.S., Burmolle M., Hansen L.H., Sorensen S.J. The interconnection between biofilm formation and horizontal gene transfer. FEMS Immunol. Med. Microbiol. 2012;65:183-195.
Not in our library10.1111/j.1574-695x.2012.00960.x
350.
Hennequin C., Aumeran C., Robin F., Traore O., Forestier C. Antibiotic resistance and plasmid transfer capacity in biofilm formed with a CTX-M-15-producing Klebsiella pneumoniae isolate. J. Antimicrob. Chemother. 2012;67:2123-2130.
Not in our library10.1093/jac/dks169
351.
Guerin E., Cambray G., Sanchez-Alberola N., Campoy S., Erill I., Da Re S., Gonzalez-Zorn B., Barbe J., Ploy M.C., Mazel D. The SOS response controls integron recombination. Science. 2009;324:1034.
Not in our library10.1126/science.1172914
352.
Hoffman L.R., D'Argenio D.A., MacCoss M.J., Zhang Z., Jones R.A., Miller S.I. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature. 2005;436:1171-1175.
Not in our library10.1038/nature03912
353.
Kohanski M.A., DePristo M.A., Collins J.J. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol. Cell. 2010;37:311-320.
Not in our library10.1016/j.molcel.2010.01.003
354.
Peters B.M., Jabra-Rizk M.A., O'May G.A., Costerton J.W., Shirtliff M.E. Polymicrobial interactions: impact on pathogenesis and human disease. Clin. Microbiol. Rev. 2012;25:193-213.
Not in our library10.1128/cmr.00013-11
355.
Wolcott R., Costerton J.W., Raoult D., Cutler S.J. The polymicrobial nature of biofilm infection. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2013;19:107-112.
Not in our library10.1111/j.1469-0691.2012.04001.x
356.
Frank D.N., Wilson S.S., St Amand A.L., Pace N.R. Culture-independent microbiological analysis of foley urinary catheter biofilms. PLoS One. 2009;4:e7811.
Not in our library10.1371/journal.pone.0007811
357.
Larsen M.K., Thomsen T.R., Moser C., Hoiby N., Nielsen P.H. Use of cultivation-dependent and -independent techniques to assess contamination of central venous catheters: a pilot study. BMC Clin. Pathol. 2008;8:10.
Not in our library10.1186/1472-6890-8-10
358.
Donelli G., Vuotto C., Cardines R., Mastrantonio P. Biofilm-growing intestinal anaerobic bacteria. FEMS Immunol. Med. Microbiol. 2012;65:318-325.
Not in our library10.1111/j.1574-695x.2012.00962.x
359.
Metabolite Cross-Feeding Enhances Virulence in a Model Polymicrobial Infection · 2011
No notice
360.
Korgaonkar A., Trivedi U., Rumbaugh K.P., Whiteley M. Community surveillance enhances Pseudomonas aeruginosa virulence during polymicrobial infection. Proc. Natl. Acad. Sci. USA. 2013;110:1059-1064.
Not in our library10.1073/pnas.1214550110
361.
Armbruster C.E., Hong W., Pang B., Weimer K.E., Juneau R.A., Turner J., Swords W.E. Indirect pathogenicity of Haemophilus influenzae and Moraxella catarrhalis in polymicrobial otitis media occurs via interspecies quorum signaling. MBio. 2010;1:e00102.
Not in our library10.1128/mbio.00102-10
362.
An In Vivo Polymicrobial Biofilm Wound Infection Model to Study Interspecies Interactions · 2011
No notice
363.
Kline K.A., Schwartz D.J., Gilbert N.M., Hultgren S.J., Lewis A.L. Immune modulation by group B Streptococcus influences host susceptibility to urinary tract infection by uropathogenic Escherichia coli. Infect. Immun. 2012;80:4186-4194.
Not in our library10.1128/iai.00684-12
364.
Conrad D., Haynes M., Salamon P., Rainey P.B., Youle M., Rohwer F. Cystic fibrosis therapy: a community ecology perspective. Am. J. Respir. Cell Mol. Biol. 2013;48:150-156.
Not in our library10.1165/rcmb.2012-0059ps
365.
Costello E.K., Stagaman K., Dethlefsen L., Bohannan B.J., Relman D.A. The application of ecological theory toward an understanding of the human microbiome. Science. 2012;336:1255-1262.
Not in our library10.1126/science.1224203
366.
Reppas A.I., Spiliotis K.G., Siettos C.I. Epidemionics: from the host-host interactions to the systematic analysis of the emergent macroscopic dynamics of epidemic networks. Virulence. 2010;1:338-349.
Not in our library10.4161/viru.1.4.12196
367.
Zur Wiesch P.A., Kouyos R., Engelstadter J., Regoes R.R., Bonhoeffer S. Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect. Dis. 2011;11:236-247.
Not in our library10.1016/s1473-3099(10)70264-4
368.
Kim H.U., Sohn S.B., Lee S.Y. Metabolic network modeling and simulation for drug targeting and discovery. Biotechnol. J. 2012;7:330-342.
Not in our library10.1002/biot.201100159
369.
Chavali A.K., D'Auria K.M., Hewlett E.L., Pearson R.D., Papin J.A. A metabolic network approach for the identification and prioritization of antimicrobial drug targets. Trends Microbiol. 2012;20:113-123.
Not in our library10.1016/j.tim.2011.12.004
370.
Sigurdsson G., Fleming R.M., Heinken A., Thiele I. A systems biology approach to drug targets in Pseudomonas aeruginosa biofilm. PLoS One. 2012;7:e34337.
Not in our library10.1371/journal.pone.0034337
371.
Fagerlind M.G., Webb J.S., Barraud N., McDougald D., Jansson A., Nilsson P., Harlen M., Kjelleberg S., Rice S.A. Dynamic modelling of cell death during biofilm development. J. Theor. Biol. 2012;295:23-36.
Not in our library10.1016/j.jtbi.2011.10.007
372.
Ilie O., van Loosdrecht M.C., Picioreanu C. Mathematical modelling of tooth demineralisation and pH profiles in dental plaque. J. Theor. Biol. 2012;309:159-175.
Not in our library10.1016/j.jtbi.2012.05.024
373.
Hindre T., Knibbe C., Beslon G., Schneider D. New insights into bacterial adaptation through in vivo and in silico experimental evolution. Nat. Rev. Microbiol. 2012;10:352-365.
Not in our library10.1038/nrmicro2750
374.
Kawecki T.J., Lenski R.E., Ebert D., Hollis B., Olivieri I., Whitlock M.C. Experimental evolution. Trends Ecol. Evol. 2012;27:547-560.
Not in our library10.1016/j.tree.2012.06.001
375.
Bianconi I., Milani A., Cigana C., Paroni M., Levesque R.C., Bertoni G., Bragonzi A. Positive signature-tagged mutagenesis in Pseudomonas aeruginosa: tracking patho-adaptive mutations promoting airways chronic infection. PLoS Pathog. 2011;7:e1001270.
Not in our library10.1371/journal.ppat.1001270
376.
Hogardt M., Heesemann J. Microevolution of Pseudomonas aeruginosa to a Chronic Pathogen of the Cystic Fibrosis Lung. Curr Top. Microbiol. Immunol. 2012;2012:91-118.
Not in our library10.1007/82_2011_199
377.
Traverse C.C., Mayo-Smith L.M., Poltak S.R., Cooper V.S. Tangled bank of experimentally evolved Burkholderia biofilms reflects selection during chronic infections. Proc. Natl. Acad. Sci. USA. 2012;110:E250-259.
Not in our library10.1073/pnas.1207025110
378.
Yang L., Jelsbak L., Marvig R.L., Damkiaer S., Workman C.T., Rau M.H., Hansen S.K., Folkesson A., Johansen H.K., Ciofu O., et al. Evolutionary dynamics of bacteria in a human host environment. Proc. Natl. Acad. Sci. USA. 2011;108:7481-7486.
Not in our library10.1073/pnas.1018249108
379.
Holmes E., Kinross J., Gibson G.R., Burcelin R., Jia W., Pettersson S., Nicholson J.K. Therapeutic modulation of microbiota-host metabolic interactions. Sci. Transl. Med. 2012;4:137rv136.
Not in our library10.1126/scitranslmed.3004244
380.
Mee M.T., Wang H.H. Engineering ecosystems and synthetic ecologies. Mol. bioSystems. 2012;8:2470-2483.
Not in our library10.1039/c2mb25133g
381.
Anderl J.N., Franklin M.J., Stewart P.S. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob. Agents Chemother. 2000;44:1818-1824.
Not in our library10.1128/aac.44.7.1818-1824.2000
382.
Zuroff T.R., Bernstein H., Lloyd-Randolfi J., Jimenez-Taracido L., Stewart P.S., Carlson R.P. Robustness analysis of culturing perturbations on Escherichia coli colony biofilm beta-lactam and aminoglycoside antibiotic tolerance. BMC Microbiol. 2010;10:185.
Not in our library10.1186/1471-2180-10-185
383.
Genevaux P., Muller S., Bauda P. A rapid screening procedure to identify mini-Tn10 insertion mutants of Escherichia coli K-12 with altered adhesion properties. FEMS Microbiol. Lett. 1996;142:27-30.
Not in our library10.1111/j.1574-6968.1996.tb08402.x
384.
Chavant P., Gaillard-Martinie B., Talon R., Hébraud M., Bernardi T. A new device for rapid evaluation of biofilm formation potential by bacteria. J. Microbiol. Methods. 2007;68:605-612.
Not in our library10.1016/j.mimet.2006.11.010
385.
Ceri H., Olson M.E., Stremick C., Read R.R., Morck D., Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 1999;37:1771-1776.
Not in our library10.1128/jcm.37.6.1771-1776.1999
386.
Merritt J.H., Kadouri D.E., O'Toole G.A. Growing and analyzing static biofilms. Current Protocols in Microbiology. 2005;Vol. 1B1:1-17.
Not in our library10.1002/9780471729259.mc01b01s00
387.
Heydorn A., Nielsen A.T., Hentzer M., Sternberg C., Givskov M., Ersbøll B.K., Molin S. Quantification of biofilm structures by the novel computer program COMSTAT. Microbiology (Reading, Engl). 2000;146:2395-2407.
Not in our library10.1099/00221287-146-10-2395
388.
Donlan R.M., Piede J.A., Heyes C.D., Sanii L., Murga R., Edmonds P., El-Sayed I., El-Sayed M.A. Model system for growing and quantifying Streptococcus pneumoniae biofilms in situ and in real time. Appl. Environ. Microbiol. 2004;70:4980-4988.
Not in our library10.1128/aem.70.8.4980-4988.2004
389.
Ghigo J.M. Natural conjugative plasmids induce bacterial biofilm development. Nature. 2001;412:442-445.
Not in our library10.1038/35086581
390.
McCoy W.F., Bryers J.D., Robbins J., Costerton J.W. Observations of fouling biofilm formation. Can. J. Microbiol. 1981;27:910-917.
Not in our library10.1139/m81-143
391.
Woods J., Boegli L., Kirker K.R., Agostinho A.M., Durch A.M., Delancey Pulcini E., Stewart P.S., James G.A. Development and application of a polymicrobial, In vitro, wound biofilm model. J. Appl. Microbiol. 2012;112:998-1006.
Not in our library10.1111/j.1365-2672.2012.05264.x
392.
Xu K.D., Stewart P.S., Xia F., Huang C.T., McFeters G.A. Spatial physiological heterogeneity in Pseudomonas aeruginosa biofilm is determined by oxygen availability. Appl. Environ. Microbiol. 1998;64:4035-4039.
Not in our library10.1128/aem.64.10.4035-4039.1998
393.
Richter L., Stepper C., Mak A., Reinthaler A., Heer R., Kast M., Bruckl H., Ertl P. Development of a microfluidic biochip for online monitoring of fungal biofilm dynamics. Lab. Chip. 2007;7:1723-1731.
Not in our library10.1039/b708236c
394.
Peters A.C., Wimpenny J.W. A constant-depth laboratory model film fermentor. Biotechnol. Bioeng. 1988;32:263-270.
Not in our library10.1002/bit.260320302
395.
Wilson M. Use of constant depth film fermentor in studies of biofilms of oral bacteria. Methods Enzymol. 1999;310:264-279.
Not in our library10.1016/s0076-6879(99)10023-5
396.
Pitts B., Willse A., McFeters G.A., Hamilton M.A., Zelver N., Stewart P.S. A repeatable laboratory method for testing the efficacy of biocides against toilet bowl biofilms. J. Appl. Microbiol. 2001;91:110-117.
Not in our library10.1046/j.1365-2672.2001.01342.x
397.
Benoit M.R., Conant C.G., Ionescu-Zanetti C., Schwartz M., Matin A. New device for high-throughput viability screening of flow biofilms. Appl. Environ. Microbiol. 2010;76:4136-4142.
Not in our library10.1128/aem.03065-09
398.
Lawrence J.R., Swerhone G.D., Neu T.R. A simple rotating annular reactor for replicated biofilm studies. J. Microbiol. Methods. 2000;42:215-224.
Not in our library10.1016/s0167-7012(00)00195-0
399.
Hodgson A.E., Nelson S.M., Brown M.R., Gilbert P. A simple In vitro model for growth control of bacterial biofilms. J. Appl. Bacteriol. 1995;79:87-93.
Not in our library10.1111/j.1365-2672.1995.tb03128.x
400.
Gilbert P., Allison D.G., Evans D.J., Handley P.S., Brown M.R. Growth rate control of adherent bacterial populations. Appl. Environ. Microbiol. 1989;55:1308-1311.
Not in our library10.1128/aem.55.5.1308-1311.1989
401.
Schaller M., Schafer W., Korting H.C., Hube B. Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol. Microbiol. 1998;29:605-615.
Not in our library10.1046/j.1365-2958.1998.00957.x
402.
Guggenheim B., Giertsen E., Schüpbach P., Shapiro S. Validation of an In vitro biofilm model of supragingival plaque. J. Dental Res. 2001;80:363-370.
Not in our library10.1177/00220345010800011201
403.
Guggenheim M., Thurnheer T., Gmur R., Giovanoli P., Guggenheim B. Validation of the Zurich burn-biofilm model. Burns J. Int. Soc. Burn Injuries. 2011;37:1125-1133.
Not in our library10.1016/j.burns.2011.05.017
404.
Grubb S.E., Murdoch C., Sudbery P.E., Saville S.P., Lopez-Ribot J.L., Thornhill M.H. Adhesion of Candidaalbicans to endothelial cells under physiological conditions of flow. Infect. Immun. 2009;77:3872-3878.
Not in our library10.1128/iai.00518-09
405.
Woodworth B.A., Tamashiro E., Bhargave G., Cohen N.A., Palmer J.N. An In vitro model of Pseudomonas aeruginosa biofilms on viable airway epithelial cell monolayers. Am. J. Rhinol. 2008;22:235-238.
Not in our library10.2500/ajr.2008.22.3178
406.
McBain A.J., Sissons C., Ledder R.G., Sreenivasan P.K., De Vizio W., Gilbert P. Development and characterization of a simple perfused oral microcosm. J. Appl. Microbiol. 2005;98:624-634.
Not in our library10.1111/j.1365-2672.2004.02483.x
407.
Kim J., Hegde M., Jayaraman A. Microfluidic co-culture of epithelial cells and bacteria for investigating soluble signal-mediated interactions. J. Vis. Exp. 2010;38:e1749.
Not in our library10.3791/1749
408.
Huang T.Y., Gulabivala K., Ng Y.L. A bio-molecular film ex vivo model to evaluate the influence of canal dimensions and irrigation variables on the efficacy of irrigation. Int. Endodontic J. 2008;41:60-71.
Not in our library10.1111/j.1365-2591.2007.01317.x
409.
Acceleration of Enterococcus faecalis biofilm formation by aggregation substance expression in an ex vivo model of cardiac valve colonization. · 2010
Not checked
410.
Carterson A.J., Honer zu Bentrup K., Ott C.M., Clarke M.S., Pierson D.L., Vanderburg C.R., Buchanan K.L., Nickerson C.A., Schurr M.J. A549 lung epithelial cells grown as three-dimensional aggregates: alternative tissue culture model for Pseudomonas aeruginosa pathogenesis. Infect. Immun. 2005;73:1129-1140.
Not in our library10.1128/iai.73.2.1129-1140.2005
411.
Nickerson C.A., Goodwin T.J., Terlonge J., Ott C.M., Buchanan K.L., Uicker W.C., Emami K., LeBlanc C.L., Ramamurthy R., Clarke M.S., et al. Three-dimensional tissue assemblies: novel models for the study of Salmonella enterica serovar Typhimurium pathogenesis. Infect. Immun. 2001;69:7106-7120.
Not in our library10.1128/iai.69.11.7106-7120.2001
412.
Smith Y.C., Grande K.K., Rasmussen S.B., O'Brien A.D. Novel three-dimensional organoid model for evaluation of the interaction of uropathogenic Escherichia coli with terminally differentiated human urothelial cells. Infect. Immun. 2006;74:750-757.
Not in our library10.1128/iai.74.1.750-757.2006
413.
Benghezal M., Adam E., Lucas A., Burn C., Orchard M.G., Deuschel C., Valentino E., Braillard S., Paccaud J.P., Cosson P. Inhibitors of bacterial virulence identified in a surrogate host model. Cell Microbiol. 2007;9:1336-1342.
Not in our library10.1111/j.1462-5822.2006.00877.x
414.
Sandstrom G., Saeed A., Abd H. Acanthamoeba-bacteria: a model to study host interaction with human pathogens. Curr. Drug Targets. 2011;12:936-941.
Not in our library10.2174/138945011795677845
415.
Annesley S.J., Fisher P.R. Dictyostelium discoideum--a model for many reasons. Mol. Cell. Biochem. 2009;329:73-91.
Not in our library10.1007/s11010-009-0111-8
416.
Silo-Suh L., Suh S.J., Sokol P.A., Ohman D.E. A simple alfalfa seedling infection model for Pseudomonas aeruginosa strains associated with cystic fibrosis shows AlgT (sigma-22) and RhlR contribute to pathogenesis. Proc. Natl. Acad. Sci. USA. 2002;99:15699-15704.
Not in our library10.1073/pnas.242343999
417.
Schlaich N.L. Arabidopsis thaliana- the model plant to study host-pathogen interactions. Curr. Drug Targets. 2011;12:955-966.
Not in our library10.2174/138945011795677863
418.
Graf J. Symbiosis of Aeromonas veronii biovar sobria and Hirudo medicinalis, the medicinal leech: a novel model for digestive tract associations. Infect. Immun. 1999;67:1-7.
Not in our library10.1128/iai.67.1.1-7.1999
419.
Laws T.R., Smith S.A., Smith M.P., Harding S.V., Atkins T.P., Titball R.W. The nematode Panagrellus redivivus is susceptible to killing by human pathogens at 37 degrees C. FEMS Microbiol. Lett. 2005;250:77-83.
Not in our library10.1016/j.femsle.2005.06.046
420.
Marsh E.K., May R.C. Caenorhabditis elegans, a model organism for investigating immunity. Appl. Environ. Microbiol. 2012;78:2075-2081.
Not in our library10.1128/aem.07486-11
421.
Jander G., Rahme L.G., Ausubel F.M. Positive correlation between virulence of Pseudomonas aeruginosa mutants in mice and insects. J. Bacteriol. 2000;182:3843-3845.
Not in our library10.1128/jb.182.13.3843-3845.2000
422.
Drosophila as a model system to unravel the layers of innate immunity to infection · 2012
No notice
423.
Kanther M., Rawls J.F. Host-microbe interactions in the developing zebrafish. Curr. Opin. Immunol. 2010;22:10-19.
Not in our library10.1016/j.coi.2010.01.006
424.
Yanagihara K., Ohnishi Y., Morinaga Y., Nakamura S., Kurihara S., Seki M., Izumikawa K., Kakeya H., Yamamoto Y., Yamada Y., et al. Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of haematogenous pulmonary infection. Int. J. Antimicrob. Agents. 2008;32:401-404.
Not in our library10.1016/j.ijantimicag.2008.04.030
425.
Yanagihara K., Seki M., Izumikawa K., Higashiyama Y., Miyazaki Y., Hirakata Y., Tomono K., Mizuta Y., Tsukamoto K., Kohno S. Potency of DX-619, a novel des-F(6)-quinolone, in haematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Int. J. Antimicrob. Agents. 2006;28:212-216.
Not in our library10.1016/j.ijantimicag.2006.03.026
426.
Rogers C.S., Hao Y., Rokhlina T., Samuel M., Stoltz D.A., Li Y., Petroff E., Vermeer D.W., Kabel A.C., Yan Z., et al. Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer. J. Clin. Invest. 2008;118:1571-1577.
Not in our library10.1172/jci34773
427.
Clerc M., Bebear C., Goursolle M., Aparicio M. Calculi experimentally obtained in the rat by intrarenal injection of Ureaplasma urealyticum. Ann. Biol. Clin. (Paris). 1984;42:277-281.
Not in our library
428.
Gurjala A.N., Geringer M.R., Seth A.K., Hong S.J., Smeltzer M.S., Galiano R.D., Leung K.P., Mustoe T.A. Development of a novel, highly quantitative in vivo model for the study of biofilm-impaired cutaneous wound healing. Wound Repair. Regen. 2011;19:400-410.
Not in our library10.1111/j.1524-475x.2011.00690.x
429.
Swords W.E., Moore M.L., Godzicki L., Bukofzer G., Mitten M.J., VonCannon J. Sialylation of lipooligosaccharides promotes biofilm formation by nontypeable Haemophilus influenzae. Infect. Immun. 2004;72:106-113.
Not in our library10.1128/iai.72.1.106-113.2004
430.
Hasturk H., Kantarci A., Goguet-Surmenian E., Blackwood A., Andry C., Serhan C.N., Van Dyke T.E. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 2007;179:7021-7029.
Not in our library10.4049/jimmunol.179.10.7021
431.
Pouliot M., Clish C.B., Petasis N.A., Van Dyke T.E., Serhan C.N. Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry. 2000;39:4761-4768.
Not in our library10.1021/bi992551b
432.
Andes D., Nett J., Oschel P., Albrecht R., Marchillo K., Pitula A. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect. Immun. 2004;72:6023-6031.
Not in our library10.1128/iai.72.10.6023-6031.2004
433.
Kurosaka Y., Ishida Y., Yamamura E., Takase H., Otani T., Kumon H. A non-surgical rat model of foreign body-associated urinary tract infection with Pseudomonas aeruginosa. Microbiol. Immunol. 2001;45:9-15.
Not in our library10.1111/j.1348-0421.2001.tb01268.x
434.
Mayberry-Carson K.J., Tober-Meyer B., Lambe D.W., Costerton J.W. An electron microscopic study of the effect of clindamycin therapy on bacterial adherence and glycocalyx formation in experimental Staphylococcus aureus osteomyelitis. Microbios. 1986;48:189-206.
Not in our library
435.
Eerenberg J.P., Patka P., Haarman H.J., Dwars B.J. A new model for posttraumatic osteomyelitis in rabbits. J. Invest. Surg. 1994;7:453-465.
Not in our library10.3109/08941939409016511
436.
Del Pozo J.L., Rouse M.S., Euba G., Kang C.I., Mandrekar J.N., Steckelberg J.M., Patel R. The electricidal effect is active in an experimental model of Staphylococcus epidermidis chronic foreign body osteomyelitis. Antimicrob. Agents Chemother. 2009;53:4064-4068.
Not in our library10.1128/aac.00432-09
437.
Poelstra K.A., Barekzi N.A., Grainger D.W., Gristina A.G., Schuler T.C. A novel spinal implant infection model in rabbits. Spine (Phila Pa 1976). 2000;25:406-410.
Not in our library10.1097/00007632-200002150-00003
438.
Li D., Gromov K., Soballe K., Puzas J.E., O'Keefe R.J., Awad H., Drissi H., Schwarz E.M. Quantitative mouse model of implant-associated osteomyelitis and the kinetics of microbial growth, osteolysis, and humoral immunity. J. Orthop. Res. 2008;26:96-105.
Not in our library10.1002/jor.20452
439.
Philipov J.P., Pascalev M.D., Aminkov B.Y., Grosev C.D. Changes in serum carboxyterminal telopeptide of type I collagen in an experimental model of canine osteomyelitis. Calcif Tissue Int. 1995;57:152-154.
Not in our library10.1007/bf00298436
440.
Williams D.L., Haymond B.S., Woodbury K.L., Beck J.P., Moore D.E., Epperson R.T., Bloebaum R.D. Experimental model of biofilm implant-related osteomyelitis to test combination biomaterials using biofilms as initial inocula. J. Biomed. Mater. Res. A. 2012;100:1888-1900.
Not in our library10.1002/jbm.a.34123
441.
Southwood R.T., Rice J.L., McDonald P.J., Hakendorf P.H., Rozenbilds M.A. Infection in experimental hip arthroplasties. J. Bone Joint Surg. Br. 1985;67:229-231.
Not in our library10.1302/0301-620x.67b2.3980532
442.
Bergamini T.M., Bandyk D.F., Govostis D., Kaebnick H.W., Towne J.B. Infection of vascular prostheses caused by bacterial biofilms. J. Vasc. Surg. 1988;7:21-30.
Not in our library
443.
Farooq M., Freischlag J., Kelly H., Seabrook G., Cambria R., Towne J. Gelatin-sealed polyester resists Staphylococcus epidermidis biofilm infection. J. Surg. Res. 1999;87:57-61.
Not in our library10.1006/jsre.1999.5729
444.
Arad E., Navon-Venezia S., Gur E., Kuzmenko B., Glick R., Frenkiel-Krispin D., Kramer E., Carmeli Y., Barnea Y. Novel Rat Model of Methicillin-Resistant Staphyloccocus aureus Infected Silicone Breast-Implants: A Study of Biofilm Pathogenesis. Plast Reconstr. Surg. 2013;131:205-214.
Not in our library10.1097/prs.0b013e3182778590
445.
Chilukuri D.M., Shah J.C. Local delivery of vancomycin for the prophylaxis of prosthetic device-related infections. Pharm Res. 2005;22:563-572.
Not in our library10.1007/s11095-005-2497-7
446.
Hessburg P.C., Truant J.P., Penn W.P. Treatment of Pseudomonas keratitis in rabbits. Am. J. Ophthalmol. 1966;61:49-54.
Not in our library10.1016/0002-9394(66)90746-x
447.
Fulcher T.P., Dart J.K., McLaughlin-Borlace L., Howes R., Matheson M., Cree I. Demonstration of biofilm in infectious crystalline keratopathy using ruthenium red and electron microscopy. Ophthalmology. 2001;108:1088-1092.
Not in our library10.1016/s0161-6420(01)00561-9
448.
Engelbert M., Gilmore M.S. Fas ligand but not complement is critical for control of experimental Staphylococcus aureus Endophthalmitis. Invest. Ophthalmol. Vis. Sci. 2005;46:2479-2486.
Not in our library10.1167/iovs.04-1139
449.
Elder M.J., Stapleton F., Evans E., Dart J.K. Biofilm-related infections in ophthalmology. Eye (Lond). 1995;9:102-109.
Not in our library10.1038/eye.1995.16
450.
Shea P.R., Virtaneva K., Kupko J.J., Porcella S.F., Barry W.T., Wright F.A., Kobayashi S.D., Carmody A., Ireland R.M., Sturdevant D.E., et al. Interactome analysis of longitudinal pharyngeal infection of cynomolgus macaques by group A Streptococcus. Proc. Natl. Acad. Sci. USA. 2010;107:4693-4698.
Not in our library10.1073/pnas.0906384107
451.
Chole R.A., Faddis B.T. Anatomical evidence of microbial biofilms in tonsillar tissues: a possible mechanism to explain chronicity. Arch. Otolaryngol. Head Neck Surg. 2003;129:634-636.
Not in our library10.1001/archotol.129.6.634
452.
Post J.C., Hiller N.L., Nistico L., Stoodley P., Ehrlich G.D. The role of biofilms in otolaryngologic infections: update 2007. Curr. Opin. Otolaryngol. Head Neck Surg. 2007;15:347-351.
Not in our library10.1097/moo.0b013e3282b97327
453.
McDuffie R.S., Kunze M., Barr J., Wolf D., Sze C.I., Shikes R., Sherman M., Gibbs R.S. Chronic intrauterine and fetal infection with Gardnerella vaginalis. Am. J. Obstet Gynecol. 2002;187:1263-1266.
Not in our library10.1067/mob.2002.127129
454.
Verstraelen H., Swidsinski A. The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment. Curr. Opin. Infect. Dis. 2013;26:86-89.
Not in our library10.1097/qco.0b013e32835c20cd
455.
Klein M., Obermaier B., Angele B., Pfister H.W., Wagner H., Koedel U., Kirschning C.J. Innate immunity to pneumococcal infection of the central nervous system depends on toll-like receptor (TLR) 2 and TLR4. J. Infect. Dis. 2008;198:1028-1036.
Not in our library10.1086/591626
456.
Neil R.B., Apicella M.A. Clinical and laboratory evidence for Neisseria meningitidis biofilms. Future Microbiol. 2009;4:555-563.
Not in our library10.2217/fmb.09.27
457.
Ruellan K., Frijns J.H., Bloemberg G.V., Hautefort C., Van den Abbeele T., Lamers G.E., Herman P., Huy P.T., Kania R.E. Detection of bacterial biofilm on cochlear implants removed because of device failure, without evidence of infection. Otol. Neurotol. 2010;31:1320-1324.
Not in our library10.1097/mao.0b013e3181e3d36b
458.
Everaert E.P., van de Belt-Gritter B., van der Mei H.C., Busscher H.J., Verkerke G.J., Dijk F., Mahieu H.F., Reitsma A. In vitro and in vivo microbial adhesion and growth on argon plasma-treated silicone rubber voice prostheses. J. Mater Sci. Mater Med. 1998;9:147-157.
Not in our library10.1023/a:1008867619481
459.
Braxton E.E., Ehrlich G.D., Hall-Stoodley L., Stoodley P., Veeh R., Fux C., Hu F.Z., Quigley M., Post J.C. Role of biofilms in neurosurgical device-related infections. Neurosurg. Rev. 2005;28:249-255.
Not in our library10.1007/s10143-005-0403-8
460.
Wilson S.K., Costerton J.W. Biofilm and penile prosthesis infections in the era of coated implants: a review. J. Sex. Med. 2012;9:44-53.
Not in our library10.1111/j.1743-6109.2011.02428.x
461.
Ginsberg G., Cope C., Shah J., Martin T., Carty A., Habecker P., Kaufmann C., Clerc C., Nuutinen J.P., Tormala P. In vivo evaluation of a new bioabsorbable self-expanding biliary stent. Gastrointest Endosc. 2003;58:777-784.
Not in our library10.1016/s0016-5107(03)02016-9
462.
Guaglianone E., Cardines R., Vuotto C., Di Rosa R., Babini V., Mastrantonio P., Donelli G. Microbial biofilms associated with biliary stent clogging. FEMS Immunol. Med. Microbiol. 2010;59:410-420.
Not in our library10.1111/j.1574-695x.2010.00686.x

Cited by papers we hold 18

Biofilm Producing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Humans: Clinical Implications and Management · 2024
No notice
Horizontal Gene Transfer of Antibiotic Resistance Genes in Biofilms · 2023
No notice
Nanotechnology as a Promising Approach to Combat Multidrug Resistant Bacteria: A Comprehensive Review and Future Perspectives · 2023
No notice
Microbial Biofilm: A Review on Formation, Infection, Antibiotic Resistance, Control Measures, and Innovative Treatment · 2023
Corrected
Bacteriophage-Mediated Control of Biofilm: A Promising New Dawn for the Future · 2022
No notice
Mimicking biofilm formation and development: Recent progress in in vitro and in vivo biofilm models · 2021
Not checked
Biofilm-Innate Immune Interface: Contribution to Chronic Wound Formation · 2021
No notice
Bacterial Biofilm Inhibition: A Focused Review on Recent Therapeutic Strategies for Combating the Biofilm Mediated Infections · 2021
No notice
Surface functionalization-dependent localization and affinity of SiO2 nanoparticles within the biofilm EPS matrix · 2020
Not checked
Unveiling the role of Gardnerella vaginalis in polymicrobial Bacterial Vaginosis biofilms: the impact of other vaginal pathogens living as neighbors · 2019
No notice
Bacterial biofilm formation on implantable devices and approaches to its treatment and prevention · 2018
Not checked
Identification of a Novel Polyamine Scaffold With Potent Efflux Pump Inhibition Activity Toward Multi-Drug Resistant Bacterial Pathogens · 2018
Not checked
On-Chip Isoniazid Exposure of <i>Mycobacterium smegmatis</i> Penicillin-Binding Protein (PBP) Mutant Using Time-Lapse Fluorescent Microscopy · 2018
Not checked
CdrA Interactions within the <named-content content-type="genus-species">Pseudomonas aeruginosa</named-content> Biofilm Matrix Safeguard It from Proteolysis and Promote Cellular Packing · 2018
Not checked
Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action · 2018
No notice
Interference in Bacterial Quorum Sensing: A Biopharmaceutical Perspective · 2018
No notice
Biofilms in Endodontics—Current Status and Future Directions · 2017
No notice
Living together in biofilms: the microbial cell factory and its biotechnological implications · 2016
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.